Repeated introductions and intensive community transmission fueled a mumps virus outbreak in Washington State

Louise H. Moncla*[1#], Allison Black[1,2#], Chas DeBolt[3], Misty Lang[3], Nicholas R. Graff[3], Ailyn C. Pérez-Osorio[3], Nicola F. Müller[1], Dirk Haselow[4], Scott Lindquist[3], Trevor Bedford*[1,2]

1. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

2. Department of Epidemiology, University of Washington, Seattle, Washington, United States

3. Office of Communicable Disease Epidemiology, Washington State Department of Health, Shoreline, Washington, United States

4. Arkansas Department of Health, Little Rock, Arkansas, United States

[#] these authors contributed equally to this work

* corresponding author; lhmoncla@gmail.com and trevor@bedford.io

Abstract

In 2016/2017, Washington State experienced a mumps outbreak despite high childhood vaccination rates, with cases more frequently detected among school-aged children and members of the Marshallese community. We sequenced 166 mumps virus genomes collected during outbreaks in Washington and other US states, and apply phylodynamic approaches to trace mumps introductions and transmission within Washington. We uncover that mumps was introduced into Washington at least 13 times, primarily from Arkansas, sparking multiple co-circulating transmission chains. Neither vaccination status nor age were strong determinants of

transmission. Instead, the outbreak in Washington was overwhelmingly sustained by transmission within the Marshallese community. Our findings underscore the utility of genomic data to clarify epidemiologic factors driving transmission, and pinpoint contact networks as critical determinants of mumps transmission. These results imply that contact structures and historic disparities may leave populations at increased risk for respiratory virus disease even when a vaccine is effective and widely used.

Introduction

In 2016 and 2017, mumps virus swept the United States in the country's largest outbreak since the pre-vaccine era (CDCMMWR, 2019). Washington State was heavily affected, reporting 889 confirmed and probable cases. Longitudinal studies (Davidkin et al., 2008), epidemiologic outbreak investigations (Cardemil et al., 2017), and epidemic models (Lewnard and Grad, 2018) suggest that mumps vaccine-induced immunity wanes over 13-30 years, consistent with the preponderance of young adult cases in recent outbreaks. Like with other recent mumps outbreaks, most Washington cases in 2016/17 were vaccinated. Unusually though, incidence was highest among children aged 10-18 years, younger than expected given waning immunity. The outbreak was also peculiar in that approximately 52% of the total cases were Marshallese, an ethnic community that comprises ~0.3% of Washington's population. These same phenomena were also observed in Arkansas. Of the 2,954 confirmed and probable Arkansas cases, 57% were Marshallese, and 57% of cases were children aged 5-17 (Fields et al., 2019). Amongst school-aged children in Arkansas and Washington, >90% had previously received 2 doses of MMR vaccine (Fields et al., 2019). The high proportion of vaccinated cases, younger-than-expected age at infection, disproportionate impact on the Marshallese community, and epidemiologic link to Arkansas suggest that factors beyond waning immunity are necessary to explain mumps transmission during this outbreak in Washington.

50

51 Between 1947 and 1986, the United States occupied the Republic of Marshall Islands and
52 detonated the equivalent of >7000 Hiroshima size nuclear bombs as part of its nuclear testing
53 program (Barker, 2012). The effects were devastating, precipitating widespread environmental
54 destruction, nuclear contamination, and dire health consequences (Hallgren et al., 2015;
55 Niedenthal, 1997; Palafox et al., 2007; Simon, 1997; Takahashi et al., 1997). Marshallese
56 individuals inhabiting the targeted atolls were forcibly moved to other islands, and many were
57 exposed to nuclear fallout (Abella et al., 2019) that persists on the Islands today (Bordner et al.,
58 2016). Significant concern remains within the community regarding long-term health impacts of
59 nuclear exposure and its potential impacts on immune function. Marshallese individuals living on
60 and off the Islands experience significant health disparities including a higher burden from
61 infectious diseases and chronic health conditions (Adams et al., 1986; Wong et al., 1979;
62 Yamada et al., 2004). Compounding these disparities, from 1996 to 2020 (Hirono, 2019),
63 Marshallese individuals were specifically excluded from Medicaid eligibility despite legal
64 residency in the US permitted under the Compact of Free Association (COFA) Treaty. As a
65 result, many US-residing Marshallese are uninsured, with poor access to healthcare (McElfish
66 et al., 2015). Marshallese households also tend to be larger on average (Harris and Jones,
67 2005; US Census Bureau, n.d.), potentially increasing risk for respiratory virus exposure.
68

69 Sampling bias is a persistent challenge for elucidating source-sink dynamics during viral
70 outbreaks. Here, we formulate a set of genomic epidemiological approaches that are robust to
71 genomic sampling to investigate patterns of mumps transmission in Washington. We sequenced
72 110 mumps viral genomes obtained from specimens collected from laboratory-confirmed
73 mumps cases in Washington State and another 56 from other US states collected between
74 2006 and 2018. We employ a novel application of phylogeographic methods to detailed

epidemiologic data on age, vaccination status, and community membership, and develop a new statistic for quantifying transmission in the tree. By combining these phylodynamic approaches with community health advocate interviews that contextualize our results, we provide a framework for investigating viral transmission dynamics that is sensitive to community health priorities and readily applicable to other viral pathogens.

Results



Figure 1: Washington case counts and genomic sampling
The first mumps case in Washington was reported on October 30, 2016, and case counts peaked in winter of 2017. The x-axis represents the date of the corresponding epidemiologic week, and the y-axis represents the number of confirmed and probable cases for that week. Blue dots above the case count plot represent the number of Washington genome sequences in our dataset sampled in that week.

Outbreak characteristics and dataset composition

We generated genome sequences for 110 PCR-positive mumps samples collected throughout Washington State during 2016/2017, and 56 samples collected in Wisconsin, Ohio, Missouri, Alabama, and North Carolina between 2006 and 2018 (**Supplemental Table 1**). The Washington State outbreak began in October 2016, and peaked in winter of 2017, culminating

94 in 889 confirmed and probable cases across Washington (**Fig. 1**). Individuals aged <1 to 64
95 years were affected, but the highest rate of infection occurred in children aged 10-14 (44.9
96 cases per 100,000) and 15-19 (47.0 per 100,000) (**Supplemental Table 2**). Among individuals
97 aged 5-19 years old, 91% were considered up-to-date on mumps vaccine. Adults in the age
98 group most likely to be parents of school aged children (20-39 years old) were infected at a rate
99 of only 12.9 cases per 100,000, but comprised a significant proportion (29%) of total cases
100 (**Supplemental Table 2**). While Marshallese individuals comprise only ~0.3% of Washington's
101 total population, they accounted for 52% of reported mumps cases (**Supplemental Table 3**).
102 Among Marshallese individuals aged 5-19, 93% were up-to-date on vaccination, suggesting that
103 this over-representation is not attributable to poor vaccine coverage.
104
105 **Outbreaks across North America are related**
106 We combined our sequence data with publicly available full genome sequences sampled from
107 North America between 2006 and 2018, and built a time-resolved phylogeny, inferring migration
108 history among 26 US states and Canadian provinces (**Fig. 2, Supplemental Figure 1**).
109 Sequences from samples collected between 2006 and 2014 clustered with other North
110 American mumps viruses sampled from the same times. Except for 2 sequences (one from
111 Wisconsin in 2006, genotype A, and one from Washington in 2017, genotype K, both excluded
112 from **Fig. 2**), all samples in our dataset were genotype G viruses. Ten Washington sequences
113 were highly divergent from other North American genotype G viruses, with a time to the most
114 recent common ancestor (TMRCA) of ~22 years (**Fig. 2**). The remaining Washington sequences
115 nest within the diversity of other North American viruses, and descend from the same mumps
116 lineage that has circulated in North America since 2006 (**Fig. 2**). We observe substantial
117 geographic mixing along the tree. While viruses from Massachusetts (dark green tips and
118 branches) seeded outbreaks in the Northeast and Midwest, we also infer transmission from



Figure 2: North American mumps outbreaks are related
We combined all publicly available North American mumps genomes and built a time-resolved phylogeny. Here, we display the maximum clade credibility tree, where each color represents a unique US state or Canadian province and the x-axis represents the collection date (for tips), or the inferred time to the most recent common ancestors (for internal nodes). We inferred geographic history using a discrete trait model. The color of each internal node represents the posterior probability of the inferred geographic location, where increasingly grey tone represents decreasing probability.

Massachusetts to Texas, Louisiana, Alabama, and British Columbia. Despite the close geographic proximity between British Columbia and Washington, most British Columbia sequences form a distinct cluster on a long branch (**Fig. 2**), suggesting seeding from an unsampled location. Although viruses from Washington are scattered throughout the phylogeny, most cluster within a clade of viruses sampled in Arkansas (**Fig. 2**).

126 **Mumps was introduced into Washington multiple independent times**

127 Estimating the number and timing of viral introductions is important for estimating epidemiologic
128 parameters and evaluating surveillance networks, but is challenging with case count data alone.
129 The Washington Department of Health had identified a single potential index case in October of
130 2016. To determine whether the genomic data supported a single introduction, we separated
131 each introduction inferred in the maximum clade credibility tree and plotted each as its own
132 transmission chain (**Fig. 3a**). We then enumerated the number of transitions into Washington in
133 each tree in the posterior set, and plotted the distribution of Washington introductions consistent
134 with the phylogeny (**Fig. 3b**).



135

136 **Figure 3: The mumps outbreak in Washington was seeded by approximately 13 introductions.** We
137 separated each introduction inferred on the maximum clade credibility tree (Figure 2) and plotted them
138 independently. Large, colored dots represent the inferred geographic location that the Washington
139 introduction was seeded from. Branches that extend earlier than July of 2016 are dotted to represent that
140 transmission likely occurred via other, unsampled locations. For reference, the cumulative case counts

141 from Arkansas and Washington are plotted below. **b.** For each tree in the posterior set, we inferred the
142 number of introductions into Washington. We plot the proportion of trees in the posterior set in which that
143 number of introductions was inferred.
144

145 Genomic data show that mumps was introduced into Washington State approximately 13
146 independent times (95% highest posterior density, HPD: 12 - 15), from geographically disparate
147 locations (**Fig. 3**). Nine sampled tips descend from long branches (~22 years), suggesting likely
148 transmission from unsampled geographic locations. We infer introductions from Ontario and
149 Missouri that each lead to 1-3 sampled cases (**Fig. 3b**), suggesting limited onward transmission
150 following these introductions. In contrast, 4 introductions from Arkansas account for 92/110
151 sequenced cases, suggesting that these introductions led to more sustained chains of
152 transmission following introduction (**Fig. 3b**). We refer to the largest cluster as the "primary
153 outbreak clade," and infer its introduction from Arkansas to Washington around August of 2016
154 (August 7, 2016, 95% HPD: July 11, 2016 to September 19, 2016, **Fig. 3b**), 3.5 months before
155 Washington's first reported case. These data reveal that what had appeared to be a single
156 outbreak based on case surveillance data was in fact a series of multiple introductions, primarily
157 from Arkansas, sparking overlapping and co-circulating transmission chains.
158

159 **SH gene sequencing is insufficient for fine-grained geographic inference**

160 Mumps virus surveillance and genotyping relies on the SH gene (Centers for Disease Control
161 and Prevention, 2019a), a short, 316 bp gene that is simple and rapid to sequence. To
162 determine whether SH gene sequencing would have produced similar results, we built a
163 divergence tree using our set of North American full genomes (**Supplemental Figure 2a**), then
164 truncated that data to include only SH gene sequences (**Supplemental Figure 2b**). Almost all
165 North American SH genes were identical, resulting in a single, large polytomy (**Supplemental**
166 **Figure 2b**). This indicates that SH sequences lack sufficient resolution to elucidate fine-grained

patterns of geographic spread, consistent with previous findings (Gouma et al., 2016; Wohl et al., 2020).

Quantifying differences in transmission patterns within Washington

In both Arkansas and Washington, Marshallese individuals comprised over 50% of mumps cases, despite accounting for a much lower proportion of the population in both states. Phylogenetic reconstruction links the outbreaks in Washington and Arkansas, placing most sampled mumps genomes in Washington as descendant from Arkansas. We sought to investigate how mumps transmission may have differed within Marshallese and non-Marshallese communities within the same outbreak. Phylogenetic trees reflect the transmission process and can be used to quantify differences in transmission patterns among population groups. If transmission rates were distinct between Marshallese and non-Marshallese mumps cases, we expect the following: 1. Sequences from the high-transmitting group should be more frequently detected upstream in transmission chains. 2. Introductions seeded into the high-transmitting group should result in larger and more diverse clades in the tree. 3. The internal nodes of the phylogeny should be predominantly composed by members of the high-transmitting group, while members of the low-transmitting group should primarily be found at terminal nodes.

Marshallese cases are enriched upstream in transmission chains

We developed a transmission metric to quantify whether Marshallese cases were enriched at the beginnings of successful transmission chains. We traverse the full genome divergence phylogeny (**Supplemental Figure 2a**) from root to tip. When we encounter a tip that lies on an internal node, we enumerate the number of tips that descend from its parent node. We then classify each tip in the phylogeny as either having descendants or not, and compare the

192 proportion of tips with and without descendants among groups (**Fig. 4a**, see Methods for more
193 details). Given our sampling proportion (110 sequences/889 total cases, ~12%), we do not
194 expect to have captured true parent/child infection pairs. Rather, we expect to have
195 preferentially sampled long, successful transmission chains within the state. This allowed us to
196 assess whether infections with particular attributes (community membership, vaccination status,
197 age) are predictors for being upstream in these chains, and thus associated with sustained
198 transmission. We evaluated the probability of having descendants in the tree as a function of
199 vaccination status, age, and community status with logistic regression (see Methods for details
200 and full model). Neither age nor vaccination status were significantly associated with the
201 presence of downstream tips in the tree (**Table 1**). However, Marshallese cases were
202 significantly more likely to have downstream descendants than non-Marshallese cases (odds
203 ratio = 3.2, p = 0.00725, **Table 1**). While only 27% (14/52) of non-Marshallese tips were
204 ancestral to downstream samples, 56% (32/57) of Marshallese tips had downstream
205 descendents. These results suggest that community membership was a significant determinant
206 of sustained transmission while controlling for vaccination status and age.

207 **Table 1: Logistic regression results of probability that phylogeny nodes has descendants**

Predictor variable	Estimated coefficient (standard error)	Odds ratio (95% CI)	p-value
Not up-to-date	-0.77 (0.69)	0.46 (0.11, 1.70)	0.26
Vaccination status unknown	0.79 (0.80)	2.21 (0.59, 9.20)	0.32
Age	-1.2 (1.44)	0.30 (0.016, 4.70)	0.41
Community status	1.17 (0.43)	3.21 (1.39, 7.69)	0.0073

208 We evaluated the impact of vaccination status, age, and community membership on the probability that
209 the phylogenetic node had descendants in the tree. Coefficients represent the increase in log odds of
210 having descendants for the given predictor variable. Coefficients were exponentiated to produce odds
211 ratios. We evaluated the impacts of having an unknown vaccination status, having a vaccination status
212 that is not up-to-date, and being Marshallese as binary predictor variables. Age was evaluated as a
213 continuous variable normalized such that values fall between 0 and 1.

214 **Longer transmission chains are associated with community status**

215 In the absence of recombination, closely-linked infections will cluster together on the tree, while
216 unrelated infections should fall disparately on the tree, forming multiple smaller clusters. We
217 inferred the number of Washington-associated clades in the tree as a function of whether
218 sampled infections came from Marshallese or non-Marshallese individuals. Using the full North
219 American phylogeny, we removed all Washington sequences and separated them into viruses
220 sampled from cases noted as Marshallese or non-Marshallese. Then, separately for each
221 group, we added sequences back into the tree one by one, until all sequences for that group
222 had been added. For each number of sequences, we performed 10 independent trials (see
223 Methods for complete details), and at each step, enumerated the number of inferred
224 Washington clusters in the phylogeny. For comparison, we also grouped tips by vaccination
225 status and repeated this analysis.

226

227 For tips from non-Marshallese individuals, the number of inferred clusters increases linearly as
228 tips are added to the tree (**Fig. 4b**). This suggests that these infections are not directly related,
229 and are not part of sustained transmission chains (**Fig. 4b**). In contrast, the number of inferred
230 clusters for Marshallese tips stabilizes after ~10 tips are added, even as almost 50 more
231 sequences are added to the tree. This pattern likely arises because many Marshallese
232 infections are part of the same long transmission chain, such that newly added tips nest within
233 existing clusters. We do not observe similar differences among vaccination groups
234 (**Supplemental Figure 3**). These findings are consistent with distinct patterns of transmission
235 among Marshallese versus non-Marshallese cases: transmission among Marshallese
236 individuals resulted in a small number of large clusters, while transmission among non-
237 Marshallese individuals are generally the result of disparate introductions that generate shorter
238 transmission chains.



Figure 4: Transmission chains are longer within the Marshallese community
a. A schematic for quantifying tips that lie "upstream" in transmission chains. For tips that lie on an internal node, i.e., have a branch length of zero, we infer the number of child tips that descend from that tip's parental node. For each tip in the example tree, the number of descendants we would infer is annotated alongside it. All tips that have a nonzero branch length are annotated as having 0 descendants. We can then compare whether sequences of particular groups (here, blue vs. red) are more likely to have descendants in the tree via logistic regression. **b.** We separated all Washington tips and classified them into Marshallese and not Marshallese. We then performed a rarefaction analysis and plot the number of inferred Washington clusters (y-axis) as a function of the number of sequences included in the analysis (x-axis). Dark blue represents not Marshallese sequences, and light blue represents Marshallese sequences. Each dot represents the number of trials in which that number of clusters was inferred, and the solid line represents the mean across trials. **c.** The exploded tree as shown in Figure 3a is shown, but tips are now colored by whether they represent Marshallese or non-Marshallese cases. For reference, the number of Washington cases (y-axis) is plotted over time (x-axis), where bar color represents whether those cases were Marshallese or not.

We next separated each Washington introduction and colored each tip by community membership. Every introduction that was not seeded from Arkansas led to exclusively non-Marshallese infections, while introductions from Arkansas defined lineages that circulated for longer and were enriched with Marshallese tips (**Fig. 4c**). The primary outbreak clade is particularly enriched, containing 43 Marshallese tips and 26 non-Marshallese tips, hinting that transmission chains are longer when Marshallese cases are present in a cluster.

263 **Mumps transmitted efficiently within the Marshallese community**

264 Internal nodes on a phylogeny represent ancestors to subsequently sampled tips, while terminal
265 nodes represent viral infections that did not give rise to sampled progeny. If the mumps
266 outbreak were primarily sustained by transmission within one group, the backbone of the
267 phylogeny and the majority of internal nodes should be inferred as circulating in that group. We
268 selected the 4 introductions that contained both Marshallese and non-Marshallese tips (**Fig. 4c**,
269 the 4 Arkansas introductions), and reconstructed ancestral states along the phylogeny and
270 migration/transmission rates between Marshallese and non-Marshallese groups using a
271 structured coalescent model.

272

273 74/88 internal nodes were inferred to circulate within the Marshallese community with posterior
274 probability of at least 0.95 (**Fig. 5a, b**). Movement of a lineage from the Marshallese deme into
275 the non-Marshallese deme subsequently caused the lineage to die out quickly (**Fig. 5a,** dark
276 blue branches). This suggests that transmission was overwhelmingly maintained within the
277 Marshallese community, and that infections seeded into the non-Marshallese community did not
278 sustain prolonged transmission chains. We estimate substantially more transmission from
279 Marshallese to non-Marshallese groups than the opposite: within the primary outbreak clade, we
280 estimate 29 transmission events from Marshallese to non-Marshallese groups (95% HPD: 21,
281 37), and only 6 (95% HPD: 0, 14) from non-Marshallese to Marshallese groups (**Fig. 5d**). This
282 strongly suggests that transmission predominantly occurred in one direction: transmission
283 events leading to non-Marshallese infections usually died out, and did not typically re-seed
284 circulation within the Marshallese community. These results hold true regardless of migration
285 rate prior (**Supplemental Figure 4**).



Figure 5: The Washington outbreak was sustained by transmission in the Marshallese community **a.** Using the 4 Washington clusters that had a mixture of Marshallese and non-Marshallese cases, we inferred phylogenies using a structured coalescent model. Each group of sequences shared a clock model, migration model, and substitution model, but each topology was inferred separately, allowing us to incorporate information from all 4 clusters into the migration estimation. For each cluster, the maximum clade credibility tree is shown, where the color of each internal node represents the posterior probability that the node is Marshallese. **b.** For each internal node shown in panel a, we plot the posterior probability of that node being Marshallese. Across all 4 clusters, 74 out of 88 internal nodes (84%) are inferred as Marshallese with a posterior probability of at least 0.95. **c.** The posterior distribution of the number of "jumps" or transmission events from Marshallese to not Marshallese (light blue) and not Marshallese to Marshallese (dark blue) inferred for the primary outbreak clade.

To ensure that our results were not driven by unequal sampling within the analyzed clades, we generated 3 datasets in which the number of Marshallese and non-Marshallese tips were subsampled to be equal. For each of these 3 subsampled datasets, we ran 3 independent chains under the same model described above. Chains converged for 2 of the 3 subsampled datasets. In the converged chains, we recover very similar tree topologies (**Supplemental Figure 5a**) with equivalent phylogenetic reconstructions of lineage circulation within Marshallese

305 and non-Marshallese demes. We also recovered maximum clade credibility trees in which the
306 vast majority of the internal nodes are inferred to circulate within the Marshallese deme
307 (**Supplemental Figure 5a,b**), confirming that our findings are robust to sampling, consistent
308 with past observations of model performance (De Maio et al., 2015; Dudas et al., 2018;
309 Vaughan et al., 2014).
310
311 The structured coalescent model requires both groups to be present in each cluster, excluding
312 several small Washington introductions composed entirely of non-Marshallese tips (**Fig. 4c**). To
313 account for this, we used all Washington genotype G sequences in our dataset and estimated a
314 single tree using an approximate structured coalescent model (Müller et al., 2018). All
315 Washington sequences were annotated as either Marshallese or not Marshallese. To provide a
316 "source" population for the extensive diversity among our disparate Washington introductions,
317 we also specified a third, unsampled deme, for which migration was only allowed to proceed
318 outward. As above, we inferred very few non-Marshallese internal nodes (**Supplemental**
319 **Figures 6 and 7**). All internal nodes in the primary outbreak group are inferred as Marshallese
320 with high probability, while non-Marshallese cases are present as terminal nodes. We recovered
321 support for a single non-Marshallese cluster, indicating limited sustained transmission in the
322 non-Marshallese population.
323
324 Structured coalescent models infer the effective population size (N_e) for each group, which
325 reflects the number of infections necessary to generate the observed genetic diversity.
326 Differences in N_e can result from different transmission rates or different numbers of infected
327 individuals (Volz, 2012), and can therefore approximate differences in disease frequency
328 between groups. While the total number of Marshallese and non-Marshallese cases reported
329 through the public health surveillance system were similar (**Supplemental Table 2**), we

330 estimate that N_e for the non-Marshallese group is approximately 3 times higher than that of the
331 Marshallese group. Assuming the same number of infected individuals in each group, lower N_e's
332 suggest higher transmission rates (Volz, 2012), suggesting more transmission within the
333 Marshallese deme. Taken together, our results suggest that the outbreak was primarily
334 sustained by transmission within the Marshallese community. While this transmission
335 sometimes spilled over into the non-Marshallese community, transmission was generally not as
336 successful there and died out, resulting in short, terminal transmission chains.
337
338 **Viruses infecting vaccination groups individuals are genetically similar**
339 Although only 9.7% of reported mumps cases in Washington were not up-to-date for mumps
340 vaccination, infection of these individuals could have disproportionately impacted transmission
341 in the state. Emergence of an antigenically novel strain of mumps could also allow infection of
342 previously vaccinated individuals, and result in different virus lineages infecting individuals in
343 different vaccination categories. We colored the tips of all Washington cases in our phylogeny to
344 represent whether they were derived from individuals who were up-to-date, not up-to-date, or
345 whose vaccination status was unknown. Mirroring overall vaccination coverage in Washington,
346 the vast majority of samples in our dataset were from up-to-date individuals. The not up-to-date
347 individuals present in our dataset are dispersed throughout the phylogeny and do not cluster
348 together (**Fig. 6**), suggesting that there is no genetic difference between viruses infecting
349 individuals with different vaccination statuses.



Figure 6: Individuals in different vaccination groups are infected by genetically similar viruses. The exploded tree as shown in Figure 3a is shown, but tips are now colored by whether they represent cases from individuals who are up-to-date for mumps vaccination, not up-to-date, or cases for which vaccination status was unknown. The color of the large dot represents the inferred geographic location from which the Washington introduction was seeded.

Discussion

The resurgence of mumps in North America has ushered renewed attention towards understanding post-vaccine era mumps transmission. While many studies have used phylodynamic approaches to elucidate viral patterns of geographic spread (Dudas et al., 2017; Gouma et al., 2016; Grubaugh et al., 2017; Stapleton et al., 2019), using genomics to distinguish transmission patterns among epidemiologically distinct groups is novel. We employ a phylogenetic method (Vaughan et al., 2014) traditionally applied to geography that is robust to sampling bias (Dudas et al., 2018) to investigate drivers of mumps transmission in Washington. We show that the Washington State outbreak was fueled by approximately 13 independent introductions, primarily from Arkansas, leading to multiple co-circulating transmission chains.

362 Within Washington, transmission was more efficient within the Marshallese community.
363 Marshallese individuals were more often sampled at the beginnings of transmission chains,
364 contributed to longer transmission chains on average, and were overwhelmingly enriched on
365 internal nodes within the phylogeny. We found no support for age or vaccination status as
366 critical determinants of transmission in our outbreak, consistent with epidemiologic findings. Our
367 data suggest that social networks can be critical determinants of mumps transmission. Future
368 work exploring how social and economic disparities may amplify respiratory disease
369 transmission will be necessary for updating outbreak mitigation and prevention strategies. By
370 combining detailed metadata, novel metrics of transmission in the tree, and robust controls for
371 sampling, we provide a framework for investigating source-sink dynamics that are readily
372 applicable to other viral pathogens.
373
374 Our results highlight the utility of genomic data to clarify epidemiologic hypotheses. While
375 genomic data and epidemiologic investigation (including case interviews and contact follow up)
376 suggested an Arkansas introduction as the Washington outbreak's primary origin, sequence
377 data revealed repeated and ongoing introductions into Washington, similar to patterns observed
378 in Massachusetts, and the Netherlands (Gouma et al., 2016; Wohl et al., 2020). We also find
379 widespread geographic mixing across the phylogeny, consistent with investigations from the US
380 (Wohl et al., 2020), Canada (Stapleton et al., 2019), and Europe (Gavilán et al., 2018; Gouma et
381 al., 2016). Like others (Gouma et al., 2016; Wohl et al., 2020), we confirm that SH genotyping
382 alone is insufficient for fine-grained resolution of geographic transmission patterns. While CDC
383 guidelines currently recommend SH-based genotyping specifically for tracking transmission
384 pathways (Clemmons et al., 2020), building public health capacity for full-genome sequencing
385 may provide better resolution for resolving local mumps transmission patterns.
386

387 Despite similar numbers of Marshallese and non-Marshallese cases, we find that mumps did not
388 transmit efficiently among the general Washington populace. Washington State uses a passive
389 surveillance system for mumps detection and case acquisition, which are known to frequently
390 result in underreporting. Because the WA Department of Health did not perform active mump
391 surveillance, it is difficult to assess whether different epidemiologic groups have different
392 likelihoods of being sampled. Marshallese individuals are less likely to seek healthcare (Towne
393 et al., 2020), which may have resulted in particularly high rates of underreporting in this group.
394 Although statewide vaccine coverage is high, the risk for acquiring and transmitting mumps is
395 clearly not equal across all Washington population groups. Provision of an outbreak dose of
396 mumps-containing vaccine to high-risk groups may therefore be especially effective for limiting
397 mumps transmission in future outbreaks. Others have reported success in using outbreak dose
398 mumps vaccinations to reduce mumps transmission on college campuses (Cardemil et al.,
399 2017; Shah et al., 2018) and in the US army (Arday et al., 1989; Eick et al., 2008; Green, 2006;
400 Kelley et al., 1991), and the CDC currently recommends providing outbreak vaccine doses to
401 individuals with increased risk due to an outbreak (Marlow et al., 2020). Future work to quantify
402 the interplay between contact rates and vaccine-induced immunity among different age and risk
403 groups should be used to guide updated vaccine recommendations.
404
405 Recent research has focused on identifying groups at risk for mumps infection due to their age
406 (Lewnard and Grad, 2018), with less attention to other factors that may make populations
407 vulnerable. In the 2016/017 Washington State outbreak, Marshallese status was a crucial
408 predictor of transmission risk. Mumps has historically caused outbreaks in communities with
409 strong, interconnected contact patterns (Barskey et al., 2012; Fields et al., 2019; Nelson et al.,
410 2013), and in dense housing environments (Snijders et al., 2012). While a combination of
411 waning immunity and dense housing settings make college campuses ideal for mumps

412 outbreaks, the Washington and Arkansas outbreaks show that populations other than young
413 adults are at risk. Soliciting feedback from a Marshallese community health advocate allowed us
414 to contextualize our genomic results with the lived experience of individuals most heavily
415 affected during the outbreak and to identify reasonable hypotheses to explain the efficient
416 transmission we observe. Based on these interviews and previously published studies, we
417 speculate that within the Marshallese community, a combination of factors likely led to a high
418 force of infection.
419
420 Multigenerational living is common in the Marshallese community (Fields et al., 2019), and
421 Marshallese households tend to be larger on average (average household size = 5.28 (Harris
422 and Jones, 2005), average household size for entire US populace = 2.52 (US Census Bureau,
423 n.d.)). Having more household contacts may have facilitated a greater number and higher
424 intensity of interactions among individuals, allowing the force of infection to overcome pre-
425 existing immunity. It is also possible that infection intensity within the Marshallese community
426 was exacerbated by low rates of insurance coverage and poor access to healthcare (McElfish et
427 al., 2017; Towne et al., 2020), hesitancy to seek medical care (Williams and Hampton, 2005),
428 and health disparities stemming from US occupation, nuclear testing, and exclusion from
429 healthcare services. As part of reparations for US nuclear testing, the US signed the Compact of
430 Free Association Treaty (COFA)(Congress, 2003) with the Marshall Islands in 1989, permitting
431 Marshallese residents to live and work in the US without visas. However, eligibility for Medicaid
432 was revoked for COFA immigrants in 1996, and US-residing Marshallese remain economically
433 disadvantaged and under-insured (McElfish, 2016; McElfish et al., 2017, 2015). The passage of
434 the Affordable Care Act (ACA) has not ameliorated these issues. Interviews with US-residing
435 Marshallese note confusion among ACA staff regarding the legal status of COFA recipients,
436 leading to drawn out enrollment processes that often leave individuals uninsured, frustrated

437 (McElfish et al., 2016), and far less likely to access care (Towne et al., 2020). A study of
438 healthcare-seeking behavior among patients with diabetes showed that while multiple factors
439 contribute to forgone care in the US populace, 77% of surveyed Marshallese individuals
440 reported recent forgeone care and cited lack of insurance as the primary reason (Towne et al.,
441 2020). Marshallese trust in US medical institutions was seriously undermined by the
442 unconsented use of Marshallese individuals for experiments on health impacts of nuclear
443 exposure, with effects lingering today (Barker, 2012). Banked historical samples confirm uptake
444 of radioactive materials in Marshallese inhabitants of affected Islands (Simon et al., 2010), but
445 there has been limited published data on long-term health impacts of nuclear exposure, and
446 significant concern remains within the community (Bordner et al., 2016). Finally, when
447 Marshallese individuals do access care, they report experiencing disdain from healthcare
448 workers (Duke, 2017) and sub-optimal care (McElfish et al., 2016). Interviews with medical
449 workers show that blame for poor Marshallese health outcomes is sometimes placed on host
450 genetics or cultural practices (Duke, 2017), poor health literacy (McElfish et al., 2018), or
451 choosing to delay care (McElfish et al., 2018), with less consideration given to how the
452 economic and legal impacts of US occupation affect the health of Marshallese individuals.
453 These factors compound, and Marshallese individuals report hesitation to seek medical care,
454 even when sick (McElfish et al., 2016). Hesitancy to seek care could have contributed to mumps
455 transmission if sick individuals were primarily cared for at home without knowledge of or the
456 ability to implement community-isolation protocols.
457
458 Our findings highlight that social networks can be the primary risk factor for a respiratory virus
459 outbreak, even when a vaccine is effective and widely used. This finding is especially pertinent
460 as SARS-CoV2 continues to disproportionately impact populations who live and work in high-
461 risk settings, including the Marshallese (Center et al., 2020; McElfish et al., 2021), and for whom

462 vaccine licensure and distribution alone may not be a panacea. The passing of federal
463 legislation remedying the exclusion of Marshallese individuals from Medicaid access (Hirono,
464 2019) in December 2020 marks an important step toward improving healthcare access for US-
465 residing Marshallese. Future work to evaluate whether this change improves Marshallese
466 access to healthcare and mitigates increased disease risk will be crucial follow-up. Future work
467 should also explore whether nuclear exposure has impacted Marshallese immune function and
468 susceptibility to infectious disease. Our findings demonstrate the importance of expanding our
469 understanding of populations at risk for mumps re-emergence, so that rapid and comprehensive
470 outbreak response strategies can be implemented to mitigate negative health impacts for all
471 affected communities. Finally, future work to disentangle the complex interplay between
472 healthcare access, social and economic disparity, and respiratory virus risk will be essential for
473 mitigating health impacts of mumps and other respiratory viruses.
474
475
476 **Materials and Methods**
477
478 **Data and Code Availability**
479 All code used to analyze data, input files for BEAST, and all code used to generate figures for
480 this manuscript are publicly available at https://github.com/blab/mumps-wa-phylodynamics. Raw
481 FASTQ files with human reads removed are available under SRA project number
482 PRJNA641715. All protocols for generating sequence data as well as the consensus genomes
483 are available at https://github.com/blab/mumps-seq. Consensus genomes have also been
484 deposited to Genbank under accessions MT859507-MT859672.
485

486 **Community feedback**

487 In order to ensure that this study was faithful to the experience of the Marshallese community in
488 Washington State, we sought paid consultation from a local Marshallese community health
489 advocate. We conducted video and telephone interviews to directly address the impacts of
490 mumps transmission on the Marshallese community, community healthcare goals and priorities,
491 and the impacts of the mumps outbreak on stigmatization. This feedback informed what is being
492 presented herein, provided crucial context for understanding mumps transmission, and allowed
493 us to work with the community to determine how best to discuss Marshallese involvement in the
494 outbreak.

495

496 **Mumps surveillance in Washington State**

497 Mumps is a notifiable condition in Washington State. Therefore, per the Washington
498 Administrative Code (WAC), as specified in WAC Chapter 246-101(Washington State
499 Legislature, 2014), healthcare providers, healthcare facilities, and laboratories must report
500 cases of mumps or possible mumps to the local health jurisdiction (LHJ) of the patient's
501 residence. LHJ staff initiate case investigations and facilitate optimal collection and testing of
502 diagnostic specimens. Buccal swabs and urine are acceptable specimens for real-time reverse
503 transcription polymerase chain reaction (qRT-PCR), a preferred diagnostic test for mumps. Most
504 mumps rRT-PCR tests for Washington State residents are performed at the Washington State
505 Public Health Laboratories, where all positive specimens are archived.

506

507 Individuals testing positive for mumps ribonucleic acid (RNA) by qRT-PCR are classified as
508 confirmed mumps cases if they have a clinically-compatible illness (i.e., an illness involving
509 parotitis or other salivary gland swelling lasting at least 2 days, aseptic meningitis, encephalitis,
510 hearing loss, orchitis, oophoritis, mastitis, or pancreatitis). During case investigations, case-

511 patients or their proxies are interviewed. Information about demographics, illness
512 characteristics, vaccination history, and potential for exposure to and transmission of mumps
513 are solicited from each case-patient. In concordance with CDC guidelines (Centers for Disease
514 Control and Prevention, 2019b), only vaccine doses for which there was written documentation
515 with the date of vaccine receipt were considered valid. Individuals for which such documentation
516 could not be provided were classified as having an unknown vaccination status. For individuals
517 with documented vaccine doses, they were further characterized as up-to-date or not up-to-date
518 based on their age. The Washington State Department of Health (DOH) receives, organizes,
519 performs quality control on, and analyzes data from, LHJ case reports and supports
520 investigations upon request.
521
522 **Sample collection and IRB approval**
523 This study was approved by the Fred Hutchinson Cancer Research Center (FHCRC)
524 Institutional Review Board (IR File #: 6007-944) and by the Washington State Institutional
525 Review Board, and classified as not involving human subjects. Samples were selected for
526 sequencing to maximize temporal and epidemiologic breadth and to ensure successful
527 sequencing. As such, samples were chosen based on the date of sample collection, the PCR
528 cycle threshold (Ct), case vaccination status, and community status (Marshallese or non-
529 Marshallese). Samples were selected for sequencing in 2 batches. In the first, samples were
530 selected based on covering a wide geographic range within Washington, a full range of dates
531 covering the outbreak, and having a Ct value < 36. This initial sampling regime resulted in a
532 sample set skewed slightly towards samples from Marshallese individuals. To ensure that the
533 proportion of samples in our data closely matched the distribution of cases in the outbreak, we
534 then selected a second batch of samples using the same criteria as above, but excluded
535 samples from Marshallese individuals. We then randomly sampled an additional 30 samples

536 from non-Marshallese individuals. This sampling regime resulted in a dataset that closely
537 mirrors the distribution of metadata categories in the outbreak overall. All metadata, including
538 case vaccination status, were transferred from WA DOH to FHCRC in a de-identified form.
539
540 We also sequenced an additional set of 56 samples collected in Wisconsin, Ohio, Missouri,
541 Alabama, and North Carolina provided by the Wisconsin State Laboratory of Hygiene. 10 of
542 these samples were collected in Wisconsin during the 2006/2007 Midwestern college campus
543 outbreaks, 6 samples were collected in 2014, and the rest were collected between 2016 and
544 2018. For these samples, we received metadata describing sample Ct value and date of
545 collection. All metadata were received by FHCRC in de-identified form.
546
547 **Viral RNA extraction, cDNA synthesis, and amplicon generation**
548 Viral RNA was extracted from buccal swabs using either the QiAmp Viral RNA Mini Kit (Qiagen,
549 Valencia, CA, USA) or the Roche MagNA Pure 96 DNA and viral NA small volume kit (Roche,
550 Basel, Switzerland). For samples extracted with the QiAmp Viral RNA Mini Kit, 500 µl of buccal
551 swab fluid was spun at 5000 x g for 5 minutes at 4°C to pellet host cells. The supernatant was
552 then removed and centrifuged at 14,000 rpm for 90 minutes at 4°C to pellet virions. Excess fluid
553 was discarded, and the peletted virions were resuspended in 150-200 µl of fluid. Resuspended
554 viral particles were then used as input to the QiAmp Viral RNA Mini Kit (Qiagen, Valencia, CA,
555 USA), following manufacturer's instructions, and eluting in 30 µl of buffer AVE. For extraction
556 with the MagNA Pure, we followed manufacturer's instructions.
557
558 cDNA was generated with the Protoscript II First strand synthesis kit (New England Biolabs,
559 Ipswich MD, USA), using 8 µl of vRNA as input and priming with 2 µl of random hexamers.
560 vRNA and primers were incubated at 65°C for 5 minutes. Following this incubation, 10 µl of

561 Protoscript II reaction mix (2x) and 2 µl of Protoscript II enzyme mix (10x) were added to each
562 reaction and incubated at 25°C for 5 minutes, then 42°C for 1 hour, followed by a final
563 inactivation step at 80°C for 5 minutes. To amplify the full mumps genomes, we used Primal
564 Scheme (http://primal.zibraproject.org/) to design overlapping, ~1500 base pair amplicons
565 spanning the entirety of the mumps virus genome, where each tiled set of primes overlapped by
566 ~100 base pairs. Primers are listed below.
567

Primer	Primer sequence	Forward/Reverse	Primer pool
mumps_1.5kb_1F	ACCAAGGGGAAAATGAAGATGGG	Forward	pool 1
mumps_1.5kb_1R	TAACGGCTGTGCTCTAAAGTCAT	Reverse	pool 1
mumps_1.5kb_2_F	TTGTTGACAGGCTTGCAAGAGG	Forward	pool 2
mumps_1.5kb_2_R	TTGTTCAAGATGTTGCAGGCGA	Reverse	pool 2
mumps_1.5kb_3_F	TGCAACCCCATATGCTCACCTA	Forward	pool 1
mumps_1.5kb_3_R	AGTTTGTTCCTGCCTTTGCACA	Reverse	pool 1
mumps_1.5kb_4_F	AGTGAGAGCAGTTCAGATGGAAGT	Forward	pool 2
mumps_1.5kb_4_R	CCCTCCATTAGACCGGCACTTA	Reverse	pool 2
mumps_1.5kb_5_F	AACAACAGTGTTCCAGCCACAA	Forward	pool 1
mumps_1.5kb_5_R	GGTGGCACTGTCCGATATTGTG	Reverse	pool 1
mumps_1.5kb_6_F	TGCCGTTCAATCATGAGACATAAAGA	Forward	pool 2
mumps_1.5kb_6_R	CGTAGAGGAGTTCATACGGCCA	Reverse	pool 2

mumps_1.5kb_7_F	TGTCTGTGCCTGGAATCAGATCT	Forward	pool 1
mumps_1.5kb_7_R	CGTCCTTCCAACATATCAGTGACC	Reverse	pool 1
mumps_1.5kb_8_F	CCAAAAGACAGGTGAGTTAACAGATTT	Forward	pool 2
mumps_1.5kb_8_R	ACGAGCAAAGGGGATGATGACT	Reverse	pool 2
mumps_1.5kb_9_F	TTTGGCACACTCCGGTTCAAAT	Forward	pool 1
mumps_1.5kb_9_R	TGACAATGGTCTCACCTCCAGT	Reverse	pool 1
mumps_1.5kb_10_F	ACTCGCACAGTATCTATTAGATCGTGA	Forward	pool 2
mumps_1.5kb_10_R	GCCCAGCCAGAGTAAACAAACA	Reverse	pool 2
mumps_1.5kb_11_F	GCCAAGCAGATGGTAAACAGCA	Forward	pool 1
mumps_1.5kb_11_R	GGCTCTCTCCAACATGCTGTTC	Reverse	pool 1
mumps_1.5kb_12_F	GCGGGGCCTCTATGTCACTTAT	Forward	pool 2
mumps_1.5kb_12_R	CCAAGGGGAGAAAGTAAAATCAAT	Reverse	pool 2

Primers were pooled into 2 pools as follows: the first contained primer pairs 1, 3, 5, 7, 9, and 11, all pooled at 10 uM. The second pool contained primer pairs 2, 4, 6, 8, 10, and 12. All primers in pool 2 were pooled at 10 uM, except for primer pair 4, which was added at a 20 uM concentration.

575 PCR was performed with the Q5 Hotstart DNA polymerase (New England Biolabs, Ipswich,
576 MD, USA), using 11.75 µl of nuclease-free water, 5 µl of Q5 reaction buffer, 0.5 µl of 10 mM
577 dNTPs, 0.25 µl, 2.5 of pooled primers, and 5 µl of cDNA. Amplicons were generated with the
578 following PCR cycling conditions: 98°C for 30 seconds, followed by 30 cycles of: 98°C for 15
579 seconds, then 67°C for 5 minutes. Cycling was concluded with a 10°C hold. PCR products were
580 run on a 1% agarose gel, and bands were cut out and purified using the QiAquick gel extraction
581 kit (Qiagen, Valencia, CA, USA), following the manufacturer's protocol. All optional steps were
582 performed, and the final product was eluted in 30 µl of buffer EB. For samples extracted on the
583 MagNA Pure, amplicons were cleaned using a 1x bead cleanup with Ampure XP beads. Final
584 cleaned amplicons were quantified using the Qubit dsDNA HS Assay kit (Thermo Fisher,
585 Waltham, MA, USA).
586
587 **Library preparation and sequencing**
588 For each sample, pool 1 and pool 2 amplicons were combined in equimolar concentrations to a
589 total of 0.5 ng in 2.5 µl. Libraries were prepared using the Nextera XT DNA Library Prep Kit
590 (Illumina, San Diego, CA, USA), following manufacturer's instructions, but with reagent volumes
591 halved for each step, for the majority of samples in our dataset. For samples processed in our
592 last sequencing run, several samples had higher Ct values. We therefore chose to process
593 these samples using the standard 1x reagent volumes for the library preparation step. All
594 libraries were purified using Ampure XP beads (Beckman Coulter, Brea, CA, USA), using a 0.6x
595 cleanup, a 1x cleanup, and a final 0.7x cleanup. At each step, beads were washed twice with
596 200-400 µl of 70% ethanol. The final product was eluted off the beads with 10 µl of buffer EB.
597 Tagmentation products were quantified with the Qubit dsDNA HS Assay kit (Thermo Fisher,
598 Waltham, MA, USA), and run on a Tapestation with the TapeStation HighSense D5K assay
599 (Agilent, Santa Clara, CA, USA) to determine the average fragment length. All but 8 samples

600 and negatives were pooled together in 6 nM libraries and run on 300 bp x 300 bp v3 kits on the
601 Illumina MiSeq, with a 1% spike-in of PhiX. The remaining 8 samples
602 (MuVs/Washington.USA/1.17/FH77[G], MuVs/Washington.USA/12.17/FH78[G],
603 MuVs/Washington.USA/16.17/FH79[G], MuVs/Washington.USA/19.17/FH80[G],
604 MuVs/Washington.USA/20.17/FH81[G], MuVs/Washington.USA/20.17/FH82[G],
605 MuVs/Washington.USA/29.17/FH83[G], and MuVs/Washington.USA/2.17/FH84[G]) were
606 pooled to a 1.2 nM library, and run as a 50 pM library with 2% PhiX on the Illumina iSeq, with a
607 151 bp x 151 bp v3 kit.

608 **Negative controls**

609 A negative control (nuclease-free water) was run for each viral RNA extraction, reverse
610 transcription reaction, and for each pool for each PCR reaction. These negative controls were
611 carried through the library preparation process and sequenced alongside actual samples. Any
612 samples whose negative controls from any step in the process resulted in >10x mumps genome
613 coverage were re-extracted and sequenced.

614 **Bioinformatic processing of sequencing reads**

615 Human reads were removed from raw FASTQ files by mapping to the human reference genome
616 GRCH38 with bowtie2 (Langmead and Salzberg, 2012) version 2.3.2 (http://bowtie-
617 bio.sourceforge.net/bowtie2/index.shtml). Reads that did not map to the human genome were
618 output to separate FASTQ files and used for all subsequent analyses. Illumina data was
619 analyzed using the pipeline described in detail at https://github.com/lmoncla/illumina_pipeline.
620 Briefly, raw FASTQ files were trimmed using Trimmomatic (Bolger et al., 2014)
621 (http://www.usadellab.org/cms/?page=trimmomatic), trimming in sliding windows of 5 base pairs
622 and requiring a minimum Q-score of 30. Reads that were trimmed to a length of <100 base
623 pairs were discarded. Trimming was performed with the following command: java -jar

624 Trimmomatic-0.36/trimmomatic-0.36.jar SE input.fastq output.fastq SLIDINGWINDOW:5:30
625 MINLEN:100. Trimmed reads were mapped to a consensus sequence from Massachusetts
626 (Genbank accession: MF965301) using bowtie2(Langmead and Salzberg, 2012) version 2.3.2
627 (http://bowtie-bio.sourceforge.net/bowtie2/index.shtml), using the following command: bowtie2 -
628 x reference_sequence.fasta -U read1.trimmed.fastq,read2.trimmed.fastq -S output.sam --local.
629 We selected this Massachusetts sequence as an initial reference sequence because at the
630 time, it represented one of the only available genomes of a genotype G mumps virus that had
631 been sampled during a US outbreak in 2016. Mapped reads were imported into Geneious
632 (https://www.geneious.com/) for visual inspection and consensus calling. To avoid issues with
633 mapping to an improper reference sequence, we then remapped each sample's trimmed
634 FASTQ files to its own consensus sequence. These bam files were again manually inspected in
635 Geneious, and a final consensus sequence was called, with nucleotide sites with <20x coverage
636 output as an ambiguous nucleotide ("N"). All genomes with >50% Ns were discarded. In total,
637 we generated 140 genomes with at least 80% non-N bases, and 26 genomes with 50-80% non-
638 N bases. Our median completeness (percent of bases that are not Ns) across the dataset is
639 90%. All genomes used in these analyses are available at https://github.com/blab/mumps-
640 seq/tree/master/data.
641
642 **Dataset curation and maximum likelihood divergence tree generation**
643 We downloaded all currently available (as of June 2020), complete mumps genomes from North
644 America from the NIAID Virus Pathogen Database and Analysis Resource (ViPR) (Pickett et al.,
645 2012) through http://www.viprbrc.org/. We also obtained mumps genomes from British
646 Columbia, Ontario, and Arkansas. We obtained written permission from sequence authors for
647 any sequence that had not previously been published on. In total, this dataset includes 437 full
648 mumps genomes from North America. Sequences and metadata were cleaned and organized

649 using fauna, a database system that is part of the Nextstrain platform. Sequences were
650 processed using Nextstrain's augur software (Hadfield et al., 2018), and filtered to include only
651 those with at least 8,000 bases and were sampled in North America in 2006 or later. Genomes
652 were aligned with MAFFT (Katoh et al., 2002), and trimmed to the reference sequence
653 (MuV/Gabon/13/2[G], GenBank accession: KM597072). We inferred a maximum likelihood
654 phylogeny using IQTREE (Nguyen et al., 2015) with a GTR nucleotide substitution model, and
655 inferred a molecular clock and temporally-resolved phylogeny using TreeTime (Sagulenko et al.,
656 2018). Sequences with an estimated clock rate that deviated from the other sequences by >4
657 times the interquartile distance were removed from subsequent analysis. We inferred the root-
658 to-tip distance with TempEst version 1.5.1 (Rambaut et al., 2016) with the best fitting root by the
659 heuristic residual mean squared function.
660
661 **Phylogenetic analysis of full North American mumps genomes**
662 Using the same set of genome sequences used for divergence tree estimation, we aligned
663 sequences with MAFFT and inferred time-resolved phylogenies in BEAST version 1.8.4
664 (Drummond et al., 2012). We used a skygrid population size prior with 100 bins, and a skygrid
665 cutoff of 25 years, allowing us to estimate 4 population sizes each year. We used an HKY
666 nucleotide substitution model with 4 gamma rate categories, and a strict clock with a CTMC
667 prior. We used a discrete trait model (Lemey et al., 2009) and estimated migration rates using
668 BSSVS and ancestral states with 27 geographic locations. Here, "state" refers to the inferred
669 ancestral identity of an internal node, where the inferred identity could be any of the 27
670 geographic locations (US states and Canadian provinces) in the dataset. For the prior on non-
671 zero rates for BSSVS, we specified an exponential distribution with a mean of 26. As a prior on
672 each pairwise migration rate, we used an exponential distribution with mean 1. All other priors
673 were left at default values. We ran this analysis for 100 million steps, sampling every 10,000,

674 and removed the first 10% of sampled states as burnin. A maximum clade credibility tree was
675 summarized with TreeAnnotator, using the mean heights option. All tree plotting was performed
676 with baltic (https://github.com/evogytis/baltic). Input XML files and output results are available at
677 https://github.com/blab/mumps-wa-phylodynamics/tree/master/phylogeography.
678

679 **Testing for descendants in divergence trees**

680 To determine whether specific groups were more likely to be found at the beginnings of
681 transmission chains than other groups, we developed a statistic to quantify transmission in the
682 tree. Using the tree JSON output from the Nextstrain pipeline (Hadfield et al., 2018), we
683 traversed the tree from root to tip. For each tip that lay on an internal node, i.e., had a branch
684 length of nearly 0 ($< 1 \times 10^{-16}$), we counted the number of descendants. We collapsed very small
685 branches (those with branch lengths less 1×10^{-16}) to obtain polytomies. We then classified tips
686 as either having descendants (i.e., the number of descendents was > 0) or not having
687 descendants. Here, we define a "descendant" as a tip that occurs in any downstream portion of
688 the tree, i.e., it falls along the same lineage but to the right of the parent tip. A diagram of what
689 we classify as "descendant tips" is shown in Figure 4a. The probability of having descendants
690 was evaluated as a function of community status, age, and vaccination status with logistic
691 regression as described below.
692

693 For each Washington tip in the tree, we classified it as either having descendants (coded as a 1)
694 or not having descendants (coded as 0). For each tip, we coded it's corresponding age,
695 vaccination status, and community membership as a predictor variable input into a logistic
696 regression model. We coded these attributes as follows: For community membership, non-
697 Marshallese tips were coded as 0 and Marshallese tips were coded as 1. Age was coded as a
698 single, continuous variable. In our dataset, there were 3 classifications for vaccination status:

699 up-to-date, not up-to-date, and unknown vaccination status. According to the Advisory
700 Committee on Immunization Practices (ACIP) (McLean et al., 2013), individuals aged 5-18 had
701 to have received both recommended doses of mumps-containing vaccine, children aged 15
702 months to 5 years required 1 dose of mumps-containing vaccine, and adults over 18 had to
703 have received at least 1 dose of mumps-containing vaccine to be classified as up-to-date for
704 mumps vaccination. Individuals under 15 months are considered up-to-date without any doses
705 of mumps-containing vaccine. Not up-to-date individuals are those with a known vaccination
706 status who did not qualify under criteria to be classified as up-to-date. Individuals who could not
707 provide documentation regarding their MMR vaccination history were considered to have
708 "unknown" vaccination status. Individuals with "known" vaccination status could either be fully
709 up-to-date, undervaccinated, or unvaccinated. To ensure that we measured the effect of
710 vaccination among individuals who knew their vaccination status, we coded vaccination
711 information using two dummy variables in our logistic regression, one signifying whether
712 vaccination status was known or not, and one indicating whether vaccination was up-to-date or
713 not. We then fit a logistic regression model to this data using the glm package in R
714 (https://www.rdocumentation.org/packages/stats/versions/3.6.2/topics/glm), specifying a
715 binomial model as
716
717 Pr(having descendants) ~ $\beta_0 + \beta_1 x_1 + \beta_2 x_2 + \beta_3 x_3 + \beta_4 x_4$, where x_1 represents 0 or 1 value for
718 member of Marshallese community (Not Marshallese coded as a 0, Marshallese coded as a 1),
719 x_2 represents the numeric value of age, x_3 represents 0 or 1 value for whether vaccination status
720 is unknown (having a known vaccination status coded as a 0, having an unknown vaccination
721 status coded as a 1) and x_4 represents 0 or 1 value for whether vaccination status is up-to-date
722 (up-to-date coded as a 0 and not up-to-date coded as a 1). Under this formulation, an individual
723 with unknown vaccination status would be coded as x_3=1, x_4=0, an individual who is up-to-date

724 would be coded as x_3=0, x_4=0, and an individual who is not up-to-date is coded as x_3=0, x_4=1.
725 This encoding allows us to evaluate the effects of having an unknown vaccination status and a
726 vaccination status that is not up-to-date. Age was normalized such that values fall between 0
727 and 1 by: (x_2 - minimum age in dataset) / (maximum age in dataset - minimum age in dataset).
728
729 P-values were assigned via a Wald test, and inferred coefficients were exponentiated to return
730 odds ratios. All code used to parse the divergence tree and formulate and fit the regression
731 model are available at https://github.com/blab/mumps-wa-
732 phylodynamics/blob/master/divergence-tree-analyses/Regression-analysis-on-descendants-in-
733 divergence-tree.ipynb.
734
735 **Rarefaction analysis to estimate transmission clusters**
736 Using the full set of North American mumps sequences, we designated all non-Washington
737 North American sequences as "background" sequences. We then separated Washington
738 sequences into Marshallese tips (57 total sequences) and non-Marshallese tips (52 total
739 sequences). For this analysis, we excluded the genotype K sequence in our dataset due to its
740 extreme divergence from other viruses sampled in Washington, which were all genotype G. For
741 each group (Marshallese vs. non-Marshallese), we then generated subsampled datasets
742 comprised of a random sample of 1 to *n* sequences, where *n* is the number of total sequences
743 available for that group. For each number of sequences, we performed 10 independent
744 subsampling trials. Subsampling was performed without replacement. So, for community
745 members, we generated 10 datasets in which 1 community member sequence was sampled,
746 then 10 datasets in which 2 community members sequences were sampled, etc. up to 10
747 datasets in which all 57 community members sequences were sampled. For each subsampled
748 dataset, we then combined these subsampled datasets with the background North American

749 sequences, and reran the Nextstrain pipeline. For each subsample and trial, we infer
750 geographic transmission history across the tree and enumerate the number of introductions into
751 Washington. Geographic transmission history was inferred using a discrete trait model in
752 TreeTime(Sagulenko et al., 2018). For each number of sequences tested, *n*, we report the
753 number of trials resulting in that number of inferred introductions, and the mean number of
754 inferred introductions across the 10 trials. Each resulting "cluster" consisted of a set of
755 sequences that are related to one another that descend from a single inferred introduction of
756 mumps into Washington.
757
758 **Inference of community transmission dynamics using a structured coalescent model**
759 To infer the rates of migration between community and non-community members and to infer
760 ancestral states of Washington internal nodes, we employed a structured coalescent model.
761 Here, "state" refers to the inferred ancestral identity of an internal node, where the identity could
762 be inferred as "Marshallese" or "not Marshallese". The multitype tree model (Vaughan et al.,
763 2014) in BEAST 2 v2.6.2 (Bouckaert et al., 2019) infers the effective population sizes of each
764 deme and the migration rates between them. Because the multitype tree model requires that all
765 partitions contain all demes, we could only analyze 4 clades that circulated in Washington State
766 and included both Marshallese and non-Marshallese tips. We generated an XML in BEAUti
767 v2.6.2 with 4 partitions, and linked the clock, site, and migration models. We used a strict, fixed
768 clock, set to 4.17×10^{-4} substitutions per site year, and used an HKY substitution model with 4
769 gamma-distributed rate categories. This clock rate was set based on the inferred substitutions
770 per site per year from all North American mumps genomes on nextstrain.org/mumps/na.
771 Migration rates were inferred with the prior specified as a truncated exponential distribution with
772 a mean of 1 and a maximum of 50. Effective population sizes were inferred with the prior
773 specified as a truncated exponential distribution with a mean of 1, a minimum value of 0.001,

774 and a maximum value of 10,000. All other priors were left at default values. In order to improve
775 convergence, we employed 3 heated chains using the package CoupledMCMC (Müller and
776 Bouckaert, 2019), where proposals for chains to swap were performed every 100 states. The
777 analysis was run for 100 million steps, with states sampled every 1 million steps. We ran this
778 analysis 3 independent times, and combined log and tree file output from those independent
779 runs using LogCombiner, with the first 10% (1000 states) of each run discarded as burnin. We
780 then summarized these combined output log and tree files. A maximum clade credibility tree
781 was inferred using TreeAnnotator with the mean heights option. To ensure that results were not
782 appreciably altered by the migration rate prior, we also repeated these analyses with migration
783 rates inferred with the prior specified as a truncated exponential distribution with a mean of 10
784 and a maximum of 50.
785
786 Although our complete dataset contains approximately equal numbers of sequences from
787 Marshallese and non-Marshallese cases, the 4 clusters analyzed above are enriched among
788 Marshallese tips. To assess the impact of uneven sampling within these clusters on ancestral
789 state inference, we performed a subsampling analysis. For each cluster, we subsampled down
790 the number of Marshallese tips to be equal to the number of non-Marshallese tips, and reran the
791 analysis as above. While the original analysis used 4 subclades containing both Marshallese
792 and non-Marshallese tips, one of these subclades only has 5 tips. Subsampling this particular
793 subtree would have resulted in a subtree with only 2 tips, thus we excluded this clade from the
794 subsampling analysis. For this sensitivity analysis, the 3 subsampled datasets had the following
795 tip composition: primary outbreak clade: 26 Marshallese and 26 non-Marshallese tips; 10-tip
796 introduction: 3 Marshallese and 3 non-Marshallese tips; 8-tip introduction: 4 Marshallese and 4
797 non-Marshallese tips. We generated 3 randomly subsampled datasets, and for each one ran 3
798 independent chains, with each chain run for 50 million steps, sampling every 500,000. For one

799 of the subsampled datasets, none of the chains converged after 20 days. In each of the
800 remaining 2 subsampled datasets, 2 out of 3 chains converged. We combined these converged
801 chains using LogCombiner, with the first 10% of each run discarded as burn-in. We then
802 summarized these combined output log and tree files, and inferred a maximum clade credibility
803 tree using TreeAnnotator with the mean heights option.
804
805 The analysis as described above assumes that each introduction into Washington State is an
806 independent observation of the same structured coalescent process, and that the dataset
807 represents a random sample of the underlying population. Additionally, this approach requires *a*
808 *priori* definition of which sequences are part of the same Washington State transmission chain.
809 Finally, the above analysis could only make use of the 4 Washington introductions with both
810 Marshallese and non-Marshallese tips, and excludes other transmission chains. Because of
811 these issues, we supplemented the above approach with an additional analysis using the
812 approximate structured coalescent (Müller et al., 2017) in MASCOT (Müller et al., 2018). Using
813 all of the Washington sequences, we specified three demes: Marshallese in Washington, non-
814 Marshallese in Washington, and outside of Washington. To account for any transmission that
815 happened outside of Washington State, the “outside of Washington” deme acted as a “ghost
816 deme” from which we did not use any samples. The effective population size of this “outside of
817 Washington” deme then describes the rate at which lineages between any location outside of
818 Washington share a common ancestor. Including specific samples from outside of Washington
819 would bias the inferred effective population size towards the coalescent rates of the sampled
820 locations, by incorporating local transmission dynamics of other locations. We then estimated
821 migration rates and effective population sizes for all 3 demes, but fixed the migration rates such
822 that the unsampled deme (“outside of Washington”) could only act as a source population. This
823 is motivated by not having observed obvious migration out of Washington State in our previous

824 analysis here. We ran this analysis for 10 million steps, sampling every 5000, and discarded the
825 first 10% of states as burnin.
826

827 ## References

828 Abella MKIL, Molina MR, Nikolić-Hughes I, Hughes EW, Ruderman MA. 2019. Background
829 gamma radiation and soil activity measurements in the northern Marshall Islands. *Proc Natl*
830 *Acad Sci U S A* **116**:15425–15434. doi:10.1073/pnas.1903421116
831 Adams WH, Fields HA, Engle JR, Hadler SC. 1986. Serologic markers for hepatitis B among
832 Marshallese accidentally exposed to fallout radiation in 1954. *Radiat Res* **108**:74–79.
833 Arday DR, Kanjarpane DD, Kelley PW. 1989. Mumps in the US Army 1980-86: should recruits
834 be immunized? *Am J Public Health* **79**:471–474. doi:10.2105/ajph.79.4.471
835 Barker HM. 2012. Bravo for the Marshallese: Regaining Control in a Post-Nuclear, Post-Colonial
836 World. Cengage Learning.
837 Barskey AE, Schulte C, Rosen JB, Handschur EF, Rausch-Phung E, Doll MK, Cummings KP,
838 Alleyne EO, High P, Lawler J, Apostolou A, Blog D, Zimmerman CM, Montana B, Harpaz R,
839 Hickman CJ, Rota PA, Rota JS, Bellini WJ, Gallagher KM. 2012. Mumps outbreak in
840 Orthodox Jewish communities in the United States. *N Engl J Med* **367**:1704–1713.
841 doi:10.1056/NEJMoa1202865
842 Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence
843 data. *Bioinformatics* **30**:2114–2120. doi:10.1093/bioinformatics/btu170
844 Bordner AS, Crosswell DA, Katz AO, Shah JT, Zhang CR, Nikolic-Hughes I, Hughes EW,
845 Ruderman MA. 2016. Measurement of background gamma radiation in the northern
846 Marshall Islands. *Proc Natl Acad Sci U S A* **113**:6833–6838. doi:10.1073/pnas.1605535113
847 Bouckaert R, Vaughan TG, Barido-Sottani J, Duchêne S, Fourment M, Gavryushkina A, Heled

848 J, Jones G, Kühnert D, De Maio N, Matschiner M, Mendes FK, Müller NF, Ogilvie HA, du
849 Plessis L, Popinga A, Rambaut A, Rasmussen D, Siveroni I, Suchard MA, Wu C-H, Xie D,
850 Zhang C, Stadler T, Drummond AJ. 2019. BEAST 2.5: An advanced software platform for
851 Bayesian evolutionary analysis. *PLoS Comput Biol* **15**:e1006650.
852 doi:10.1371/journal.pcbi.1006650
853 Cardemil CV, Dahl RM, James L, Wannemuehler K, Gary HE, Shah M, Marin M, Riley J, Feikin
854 DR, Patel M, Quinlisk P. 2017. Effectiveness of a Third Dose of MMR Vaccine for Mumps
855 Outbreak Control. *N Engl J Med* **377**:947–956. doi:10.1056/NEJMoa1703309
856 CDCMMWR. 2019. Notifiable Diseases and Mortality Tables.
857 Center KE, Da Silva J, Hernandez AL, Vang K, Martin DW, Mazurek J, Lilo EA, Zimmerman NK,
858 Krow-Lucal E, Campbell EM, Cowins JV, Walker C, Dominguez KL, Gallo B, Gunn JKL,
859 McCormick D, Cochran C, Smith MR, Dillaha JA, James AE. 2020. Multidisciplinary
860 Community-Based Investigation of a COVID-19 Outbreak Among Marshallese and
861 Hispanic/Latino Communities - Benton and Washington Counties, Arkansas, March-June
862 2020. *MMWR Morb Mortal Wkly Rep* **69**:1807–1811. doi:10.15585/mmwr.mm6948a2
863 Centers for Disease Control and Prevention. 2019a. Health Departments: How to Optimize
864 Mumps Testing | CDC. *Guidance for Optimizing Mumps Testing*.
865 https://www.cdc.gov/mumps/health-departments/optimize-testing.html
866 Centers for Disease Control and Prevention. 2019b. Epidemiology and Prevention of Vaccine-
867 Preventable Diseases, The Pink Book: Course Textbook. Centers for Disease Control and
868 Prevention.
869 Clemmons N, Hickman C, Lee A, Mona Marin M, Patel M. 2020. Manual for the Surveillance of
870 Vaccine-Preventable Diseases. Centers for Disease Control and Prevention.
871 Congress 108th United States. 2003. Compact of Free Association Amendments Act of 2003.
872 Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. 2008. Persistence of measles, mumps,

873 and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. *J Infect Dis*
874 **197**:950–956. doi:10.1086/528993
875 De Maio N, Wu CH, O'Reilly KM, Wilson D. 2015. New Routes to Phylogeography: A Bayesian
876 Structured Coalescent Approximation. *PLoS Genet*. doi:10.1371/journal.pgen.1005421
877 Drummond AJ, Suchard MA, Xie D, Rambaut A. 2012. Bayesian phylogenetics with BEAUti and
878 the BEAST 1.7. *Mol Biol Evol* **29**:1969–1973. doi:10.1093/molbev/mss075
879 Dudas G, Carvalho LM, Bedford T, Tatem AJ, Baele G, Faria NR, Park DJ, Ladner JT, Arias A,
880 Asogun D, Bielejec F, Caddy SL, Cotten M, D'Ambrozio J, Dellicour S, Di Caro A, Diclaro
881 JW, Duraffour S, Elmore MJ, Fakoli LS, Faye O, Gilbert ML, Gevao SM, Gire S, Gladden-
882 Young A, Gnirke A, Goba A, Grant DS, Haagmans BL, Hiscox JA, Jah U, Kugelman JR, Liu
883 D, Lu J, Malboeuf CM, Mate S, Matthews DA, Matranga CB, Meredith LW, Qu J, Quick J,
884 Pas SD, Phan MVT, Pollakis G, Reusken CB, Sanchez-Lockhart M, Schaffner SF,
885 Schieffelin JS, Sealfon RS, Simon-Loriere E, Smits SL, Stoecker K, Thorne L, Tobin EA,
886 Vandi MA, Watson SJ, West K, Whitmer S, Wiley MR, Winnicki SM, Wohl S, Wölfel R,
887 Yozwiak NL, Andersen KG, Blyden SO, Bolay F, Carroll MW, Dahn B, Diallo B, Formenty
888 P, Fraser C, Gao GF, Garry RF, Goodfellow I, Günther S, Happi CT, Holmes EC, Kargbo B,
889 Keïta S, Kellam P, Koopmans MPG, Kuhn JH, Loman NJ, Magassouba N 'faly, Naidoo D,
890 Nichol ST, Nyenswah T, Palacios G, Pybus OG, Sabeti PC, Sall A, Ströher U, Wurie I,
891 Suchard MA, Lemey P, Rambaut A. 2017. Virus genomes reveal factors that spread and
892 sustained the Ebola epidemic. *Nature* **544**:309–315. doi:10.1038/nature22040
893 Dudas G, Carvalho LM, Rambaut A, Bedford T. 2018. MERS-CoV spillover at the camel-human
894 interface. *Elife*. doi:10.7554/eLife.31257
895 Duke MR. 2017. Neocolonialism and Health Care Access among Marshall Islanders in the
896 United States. *Med Anthropol Q* **31**:422–439. doi:10.1111/maq.12376
897 Eick AA, Hu Z, Wang Z, Nevin RL. 2008. Incidence of mumps and immunity to measles, mumps

898 and rubella among US military recruits, 2000-2004. *Vaccine* **26**:494–501.
899 doi:10.1016/j.vaccine.2007.11.035
900 Fields VS, Safi H, Waters C, Dillaha J, Capelle L, Riklon S, Wheeler JG, Haselow DT. 2019.
901 Mumps in a highly vaccinated Marshallese community in Arkansas, USA: an outbreak
902 report. *Lancet Infect Dis* **19**:185–192. doi:10.1016/S1473-3099(18)30607-8
903 Gavilán AM, Fernández-García A, Rueda A, Castellanos A, Masa-Calles J, López-Perea N,
904 Torres de Mier MV, de Ory F, Echevarría JE. 2018. Genomic non-coding regions reveal
905 hidden patterns of mumps virus circulation in Spain, 2005 to 2015. *Euro Surveill* **23**.
906 doi:10.2807/1560-7917.ES.2018.23.15.17-00349
907 Gouma S, Cremer J, Parkkali S, Veldhuijzen I, van Binnendijk RS, Koopmans MPG. 2016.
908 Mumps virus F gene and HN gene sequencing as a molecular tool to study mumps virus
909 transmission. *Infect Genet Evol* **45**:145–150. doi:10.1016/j.meegid.2016.08.033
910 Green CB. 2006. Updated Vaccine Guidance for Adults and Accessions-June 2006.
911 Grubaugh ND, Ladner JT, Kraemer MUG, Dudas G, Tan AL, Gangavarapu K, Wiley MR, White
912 S, Thézé J, Magnani DM, Prieto K, Reyes D, Bingham AM, Paul LM, Robles-Sikisaka R,
913 Oliveira G, Pronty D, Barcellona CM, Metsky HC, Baniecki ML, Barnes KG, Chak B, Freije
914 CA, Gladden-Young A, Gnirke A, Luo C, MacInnis B, Matranga CB, Park DJ, Qu J,
915 Schaffner SF, Tomkins-Tinch C, West KL, Winnicki SM, Wohl S, Yozwiak NL, Quick J,
916 Fauver JR, Khan K, Brent SE, Reiner RC Jr, Lichtenberger PN, Ricciardi MJ, Bailey VK,
917 Watkins DI, Cone MR, Kopp EW 4th, Hogan KN, Cannons AC, Jean R, Monaghan AJ,
918 Garry RF, Loman NJ, Faria NR, Porcelli MC, Vasquez C, Nagle ER, Cummings DAT,
919 Stanek D, Rambaut A, Sanchez-Lockhart M, Sabeti PC, Gillis LD, Michael SF, Bedford T,
920 Pybus OG, Isern S, Palacios G, Andersen KG. 2017. Genomic epidemiology reveals
921 multiple introductions of Zika virus into the United States. *Nature* **546**:401–405.
922 doi:10.1038/nature22400

923 Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P, Bedford T,
924 Neher RA. 2018. Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics*
925 **34**:4121–4123. doi:10.1093/bioinformatics/bty407
926 Hallgren EA, McElfish PA, Rubon-Chutaro J. 2015. Barriers and opportunities: a community-
927 based participatory research study of health beliefs related to diabetes in a US Marshallese
928 community. *Diabetes Educ* **41**:86–94. doi:10.1177/0145721714559131
929 Harris PM, Jones NA. 2005. We the People: Pacific Islanders in the United States. US
930 Department of Commerce.
931 Hirono MK. 2019. Covering our FAS Allies Act.
932 Katoh K, Misawa K, Kuma KK-I, Miyata T. 2002. MAFFT: a novel method for rapid multiple
933 sequence alignment based on fast Fourier transform. *Nucleic Acids Res* **30**:3059–3066.
934 doi:10.1093/nar/gkf436
935 Kelley PW, Petruccelli BP, Stehr-Green P, Erickson RL, Mason CJ. 1991. The susceptibility of
936 young adult Americans to vaccine-preventable infections. A national serosurvey of US
937 Army recruits. *JAMA* **266**:2724–2729. doi:10.1001/jama.1991.03470190072032
938 Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. *Nat Methods*
939 **9**:357–359. doi:10.1038/nmeth.1923
940 Lemey P, Rambaut A, Drummond AJ, Suchard MA. 2009. Bayesian phylogeography finds its
941 roots. *PLoS Comput Biol*. doi:10.1371/journal.pcbi.1000520
942 Lewnard JA, Grad YH. 2018. Vaccine waning and mumps re-emergence in the United States.
943 *Sci Transl Med* **10**. doi:10.1126/scitranslmed.aao5945
944 Marlow MA, Marin M, Moore K, Patel M. 2020. CDC Guidance for Use of a Third Dose of MMR
945 Vaccine During Mumps Outbreaks. *J Public Health Manag Pract* **26**:109–115.
946 doi:10.1097/PHH.0000000000000962
947 McElfish PA. 2016. Marshallese COFA Migrants in Arkansas. *J Ark Med Soc* **112**:259–60, 262.

948 McElfish PA, Chughtai A, Low LK, Garner R, Purvis RS. 2018. “Just doing the best we can”:
949 health care providers’ perceptions of barriers to providing care to Marshallese patients in
950 Arkansas. *Ethn Health* 1–14. doi:10.1080/13557858.2018.1471670
951 McElfish PA, Hallgren E, Yamada S. 2015. Effect of US health policies on health care access
952 for Marshallese migrants. *Am J Public Health* **105**:637–643.
953 doi:10.2105/AJPH.2014.302452
954 McElfish PA, Purvis RS, Maskarinec GG, Bing WI, Jacob CJ, Ritok-Lakien M, Rubon-Chutaro J,
955 Lang S, Mamis S, Riklon S. 2016. Interpretive policy analysis: Marshallese COFA migrants
956 and the Affordable Care Act. *Int J Equity Health* **15**:91. doi:10.1186/s12939-016-0381-1
957 McElfish PA, Purvis R, Willis DE, Riklon S. 2021. COVID-19 Disparities Among Marshallese
958 Pacific Islanders. *Prev Chronic Dis* **18**:E02. doi:10.5888/pcd18.200407
959 McElfish PA, Rowland B, Long CR, Hudson J, Piel M, Buron B, Riklon S, Bing WI, Warmack TS.
960 2017. Diabetes and Hypertension in Marshallese Adults: Results from Faith-Based Health
961 Screenings. *J Racial Ethn Health Disparities* **4**:1042–1050. doi:10.1007/s40615-016-0308-y
962 McLean HQ, Amy Parker Fiebelkorn MSN, Temte JL, Wallace GS. 2013. Prevention of
963 Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013.
964 https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm
965 Müller NF, Bouckaert R. 2019. Coupled MCMC in BEAST 2. *bioRxiv*. doi:10.1101/603514
966 Müller NF, Rasmussen DA, Stadler T. 2017. The Structured Coalescent and Its Approximations.
967 *Molecular Biology and Evolution*. doi:10.1093/molbev/msx186
968 Müller NF, Rasmussen D, Stadler T. 2018. MASCOT: parameter and state inference under the
969 marginal structured coalescent approximation. *Bioinformatics*.
970 doi:10.1093/bioinformatics/bty406
971 Nelson GE, Aguon A, Valencia E, Oliva R, Guerrero ML, Reyes R, Lizama A, Diras D, Mathew
972 A, Camacho EJ, Monforte M-N, Chen T-H, Mahamud A, Kutty PK, Hickman C, Bellini WJ,

973 Seward JF, Gallagher K, Fiebelkorn AP. 2013. Epidemiology of a mumps outbreak in a
974 highly vaccinated island population and use of a third dose of measles-mumps-rubella
975 vaccine for outbreak control--Guam 2009 to 2010. *Pediatr Infect Dis J* **32**:374–380.
976 doi:10.1097/INF.0b013e318279f593
977 Nguyen L-T, Schmidt HA, von Haeseler A, Minh BQ. 2015. IQ-TREE: a fast and effective
978 stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol Biol Evol* **32**:268–
979 274. doi:10.1093/molbev/msu300
980 Niedenthal J. 1997. A history of the people of Bikini following nuclear weapons testing in the
981 Marshall Islands: with recollections and views of elders of Bikini Atoll. *Health Phys* **73**:28–
982 36. doi:10.1097/00004032-199707000-00003
983 Palafox NA, Riklon S, Alik W, Hixon AL. 2007. Health consequences and health systems
984 response to the Pacific U.S. Nuclear Weapons Testing Program. *Pac Health Dialog*
985 **14**:170–178.
986 Pickett BE, Sadat EL, Zhang Y, Noronha JM, Squires RB, Hunt V, Liu M, Kumar S, Zaremba S,
987 Gu Z, Zhou L, Larson CN, Dietrich J, Klem EB, Scheuermann RH. 2012. ViPR: an open
988 bioinformatics database and analysis resource for virology research. *Nucleic Acids Res*
989 **40**:D593–8. doi:10.1093/nar/gkr859
990 Rambaut A, Lam TT, Max Carvalho L, Pybus OG. 2016. Exploring the temporal structure of
991 heterochronous sequences using TempEst (formerly Path-O-Gen). *Virus Evol* **2**:vew007.
992 doi:10.1093/ve/vew007
993 Sagulenko P, Puller V, Neher RA. 2018. TreeTime: Maximum-likelihood phylodynamic analysis.
994 *Virus Evolution* **4**. doi:10.1093/ve/vex042
995 Shah M, Quinlisk P, Weigel A, Riley J, James L, Patterson J, Hickman C, Rota PA, Stewart R,
996 Clemmons N, Kalas N, Cardemil C, Iowa Mumps Outbreak Response Team. 2018. Mumps
997 Outbreak in a Highly Vaccinated University-Affiliated Setting Before and After a Measles-

998 Mumps-Rubella Vaccination Campaign-Iowa, July 2015-May 2016. *Clin Infect Dis* **66**:81–
999 88. doi:10.1093/cid/cix718
1000 Simon SL. 1997. A brief history of people and events related to atomic weapons testing in the
1001 Marshall Islands. *Health Phys* **73**:5–20. doi:10.1097/00004032-199707000-00001
1002 Simon SL, Bouville A, Melo D, Beck HL, Weinstock RM. 2010. Acute and chronic intakes of
1003 fallout radionuclides by Marshallese from nuclear weapons testing at Bikini and Enewetak
1004 and related internal radiation doses. *Health Phys* **99**:157–200.
1005 doi:10.1097/HP.0b013e3181dc4e51
1006 Snijders BEP, van Lier A, van de Kassteele J, Fanoy EB, Ruijs WLM, Hulshof F, Blauwhof A,
1007 Schipper M, van Binnendijk R, Boot HJ, de Melker HE, Hahné SJM. 2012. Mumps vaccine
1008 effectiveness in primary schools and households, the Netherlands, 2008. *Vaccine* **30**:2999–
1009 3002. doi:10.1016/j.vaccine.2012.02.035
1010 Stapleton PJ, Eshaghi A, Seo CY, Wilson S, Harris T, Deeks SL, Bolotin S, Goneau LW,
1011 Gubbay JB, Patel SN. 2019. Evaluating the use of whole genome sequencing for the
1012 investigation of a large mumps outbreak in Ontario, Canada. *Sci Rep* **9**:12615.
1013 doi:10.1038/s41598-019-47740-1
1014 Takahashi T, Trott KR, Fujimori K, Simon SL, Ohtomo H, Nakashima N, Takaya K, Kimura N,
1015 Satomi S, Schoemaker MJ. 1997. An investigation into the prevalence of thyroid disease on
1016 Kwajalein Atoll, Marshall Islands. *Health Phys* **73**:199–213. doi:10.1097/00004032-
1017 199707000-00017
1018 Towne SD, Yeary KHK, Narcisse M-R, Long C, Bursac Z, Totaram R, Rodriguez EM, McElfish
1019 P. 2020. Inequities in Access to Medical Care Among Adults Diagnosed with Diabetes:
1020 Comparisons Between the US Population and a Sample of US-Residing Marshallese
1021 Islanders. *J Racial Ethn Health Disparities*. doi:10.1007/s40615-020-00791-x
1022 US Census Bureau. n.d. Historical Households Tables.

1023 Vaughan TG, Kühnert D, Popinga A, Welch D, Drummond AJ. 2014. Efficient Bayesian
1024 inference under the structured coalescent. *Bioinformatics*.
1025 doi:10.1093/bioinformatics/btu201
1026 Volz EM. 2012. Complex population dynamics and the coalescent under neutrality. *Genetics*
1027 **190**:187–201. doi:10.1534/genetics.111.134627
1028 Washington State Legislature. 2014. Chapter 246-101 WAC. *Chapter 246-101 WAC Notifiable*
1029 *Conditions*. https://app.leg.wa.gov/wac/default.aspx?cite=246-101
1030 Williams DP, Hampton A. 2005. Barriers to health services perceived by Marshallese
1031 immigrants. *J Immigr Health* **7**:317–326. doi:10.1007/s10903-005-5129-8
1032 Wohl S, Metsky HC, Schaffner SF, Piantadosi A, Burns M, Lewnard JA, Chak B, Krasilnikova
1033 LA, Siddle KJ, Matranga CB, Bankamp B, Hennigan S, Sabina B, Byrne EH, McNall RJ,
1034 Shah RR, Qu J, Park DJ, Gharib S, Fitzgerald S, Barreira P, Fleming S, Lett S, Rota PA,
1035 Madoff LC, Yozwiak NL, MacInnis BL, Smole S, Grad YH, Sabeti PC. 2020. Combining
1036 genomics and epidemiology to track mumps virus transmission in the United States. *PLoS*
1037 *Biol* **18**:e3000611. doi:10.1371/journal.pbio.3000611
1038 Wong DC, Purcell RH, Rosen L. 1979. Prevalence of antibody to hepatitis A and hepatitis B
1039 viruses in selected populations of the South Pacific. *Am J Epidemiol* **110**:227–236.
1040 doi:10.1093/oxfordjournals.aje.a112807
1041 Yamada S, Dodd A, Soe T, Chen T-H, Bauman K. 2004. Diabetes mellitus prevalence in out-
1042 patient Marshallese adults on Ebeye Island, Republic of the Marshall Islands. *Hawaii Med J*
1043 **63**:45–51.

1044

1045 **Acknowledgments**

1046 We would like to extend our sincerest thank you to Jiji Jally for her help and input on the project.
1047 Jiji Jally is an advocate for affordable access to healthcare services, supportive services for the
1048 Marshallese community, and works as a translator to assist the community in Washington State.
1049 These insightful discussions were absolutely critical for contextualizing our results. We would
1050 also like to sincerely thank Kelsey Florek for locating and sharing mumps samples from
1051 Wisconsin, Ohio, Missouri, Alabama, and North Carolina, which greatly enhanced the analyses
1052 presented here. We also thank Jeff Joy for graciously sharing mumps genomes from British
1053 Columbia. Finally, we would like to thank the Fred Hutchinson Cancer Research Center
1054 sequencing core for providing excellent sequencing services and Fred Hutch Scientific
1055 Computing Infrastructure. LHM is an Open Philanthropy Project fellow of the Life Sciences
1056 Research Foundation. AB was supported by the National Science Foundation Graduate
1057 Research Fellowship Program under Grant No. DGE-1256082. TB is a Pew Biomedical Scholar
1058 and is supported by NIH R35 GM119774-01. Scientific Computing Infrastructure at Fred Hutch
1059 is supported by NIH ORIP S10OD028685.
1060

1061 **Author contributions**

1062 LHM and AB generated and analyzed data and wrote the manuscript. CD and NRG provided
1063 data and contributed to writing the manuscript. ML, APO, and SL, provided sample and support
1064 for the study. DH provided conceptual input and contributed to the writing of the manuscript.
1065 NFM analyzed data and helped write the manuscript. TB planned the study, supported data
1066 analysis, and wrote the manuscript.
1067
1068



Supplemental Figure 1: Mumps genomes accumulate mutations linearly over time
We inferred a maximum likelihood phylogeny using IQTREE for all available complete mumps genomes of genotype G, sampled from North America between 2006 and 2018. We inferred the root-to-tip distance with TempEst and plot the root to tip divergence vs. sample collection date. Color represents geographic location (either Canadian province or US state), with colors corresponding to those in Figure 2. We infer that mumps genomes accumulate mutations at a rate of 3.75×10^{-4} substitutions per site per year.



Supplemental Figure 2: SH gene sequences are inadequate for fine-scale resolution of mumps tranmission

a. We inferred a maximum likelihood phylogeny using IQTREE for all available complete mumps genomes of genotype G, sampled from North America between 2006 and 2018. Color represents geographic location (either Canadian province or US state), and the x-axis displays divergence in substitutions per site per year. **b.** To compare whether similar results would have been obtained if we had only sequenced the SH gene, we truncated our sequences to include only the coding region for SH and again inferred a maximum likelihood phylogeny using the same procedure as in a. The vast majority of North American mumps sequences are identical and form a single polytomy, suggesting that SH sequencing alone provides limited resolution for inferring geographic spread.



Supplemental Figure 3: Rarefaction results by vaccination status
We repeated the rarefaction analysis shown in Figure 4b for vaccination status. We separated all Washington tips and classified them by vaccination status into up-to-date, not up-to-date, or unknown vaccination status. We then performed a rarefaction analysis and plot the number of inferred Washington clusters (y-axis) as a function of the number of sequences included in the analysis (x-axis). Dark green represents unknown vaccination status, light green represents not up-to-date, and green represents up-to-date. The majority of sequences in our dataset were derived from individuals who were up-to-date for mumps vaccine. Each dot represents the number of trials in which that number of clusters was inferred, and the solid line represents the mean across trials.



Supplemental Figure 4: Inferences are similar under a higher migration rate prior
The results are shown for the exact same analyses displayed in Figure 5, except inferred under a model with a higher migration rate prior (10 instead of 1). **a.** Using the 4 Washington clusters that had a mixture of Marshallese and non-Marshallese cases, we inferred phylogenies using a structured coalescent model. Each group of sequences shared a clock model, migration model, and substitution model, but each topology was inferred separately, allowing us to incorporate information from all 4 clusters into the migration estimation. For each cluster, the maximum clade credibility tree is shown, where the color of each internal node represents the posterior probability that the node is Marshallese. **b.** For each internal node shown in panel **a**, we plot the posterior probability of that node being Marshallese. Across all 4 clusters, almost every internal node is inferred as Marshallese with high probability. **c.** The posterior distribution of the number of "jumps" or transmission events from Marshallese to not Marshallese (light blue) and not Marshallese to Marshallese (dark blue) inferred for the primary outbreak clade.



Supplemental Figure 5: Structured coalesent analyses are robust to sampling differences
To ensure that our results were robust to differences in sampling of Marshallese and non-Marshallese tips within the clusters used for this analysis, we subsampled our dataset 3 independent times, and ran 3 independent chains per unique subsampling. In each subsampled dataset, the number of Marshallese tips was randomly subsampled to be equal to the number of non-Marshallese tips in each of the 4 clusters. We then ran each of these subsampled datasets with the exact same model as run with the full dataset. In subsampled datasets 1 and 2, 2 out of 3 chains converged, and results were combined and displayed here. In the 3rd subsampled dataset, none of the 3 chains converged, so those results are not shown. **a.** For each subsampled dataseet, we plot the inferred maximum clade credibility tree from the combined tree outputs from the 2 converged chains. The color of each tip represents whether that sample was derived from a Marshallese or non-Marshallese case, and the color of the internal node represents the posterior probability of that internal node being Marshallese. **b.** For each tree shown in **a**, the posterior probability that each internal node is labelled as Marshallese is shown. The number of the subsampled dataset is shown on the x-axis and the posterior probability is shown on the y-axis.



Supplemental Figure 6: Including all Washington sequences recovers majority of transmission in Marshallese

To ensure that excluding non-Marshallese clusters did not skew our findings, we inferred a single tree using all Washington sequences. We performed a structured coalescent analysis specifying 3 groups: Marshallese, not Marshallese, and not Washington. Each internal node is colored by its most probable group, with its opacity specifying the posterior probability of being in that group (fully opaque being probability = 1, fully transparent being probability = 0).



Supplemental Figure 7: Posterior probabilities of internal node states
a. For the tree shown in Supplemental Figure 6, each internal node is plotted. For each intenral node, its color and placement on the x-axis represents its inferred most probable group (Marshallese, Not Marshallese, or Not Washington). The posterior probability of being labelled its most probable group is shown on the y-axis. We recover moderate support for a small number of non-Marshallese internal nodes, while the vast majority of internal nodes remain inferred as Marshallese. **b.** The 95% highest posterior density intervals of the inferred effective population sizes for Marshallese, non-Marshallese, and not Washington demes.

Supplemental Table 1: Sample metadata

Strain name	Sample type	Country	US state	Mumps genotype	Vaccination status	Cycle threshold (Ct)	Genome coverage
MuVs/Washington.USA/48.16/FH1[G]	Buccal Swab	USA	Washington	G	up-to-date	29.32	0.91
MuVs/Washington.USA/50.16/FH2[G]	Buccal Swab	USA	Washington	G	up-to-date	25.11	0.93
MuVs/Washington.USA/50.16/FH3[G]	Buccal Swab	USA	Washington	G	up-to-date	28.53	0.84
MuVs/Washington.USA/50.16/FH4[G]	Buccal Swab	USA	Washington	G	unknown	27.51	0.84
MuVs/Washington.USA/1.17/FH5[G]	Buccal Swab	USA	Washington	G	up-to-date	23.04	0.93
MuVs/Washington.USA/1.17/FH6[G]	Buccal Swab	USA	Washington	G	not up-to-date	32.87	0.93
MuVs/Washington.USA/1.17/FH7[G]	Buccal Swab	USA	Washington	G	up-to-date	25.29	0.92
MuVs/Washington.USA/1.17/FH8[G]	Buccal Swab	USA	Washington	G	unknown	26.61	0.93
MuVs/Washington.USA/5.17/FH9[G]	Buccal Swab	USA	Washington	G	up-to-date	30.38	0.84
MuVs/Washington.USA/5.17/FH10[G]	Buccal Swab	USA	Washington	G	up-to-date	26.72	0.92
MuVs/Washington.USA/5.17/FH11[G]	Buccal Swab	USA	Washington	G	up-to-date	28.17	0.93
MuVs/Washington.USA/6.17/FH12[G]	Buccal Swab	USA	Washington	G	unknown	25.00	0.93

MuVs/Washington.USA/6.17/FH13[G]	Buccal Swab	USA	Washington	G	up-to-date	25.31	0.93
MuVs/Washington.USA/6.17/FH14[G]	Buccal Swab	USA	Washington	G	unknown	29.04	0.93
MuVs/Washington.USA/7.17/FH15[G]	Buccal Swab	USA	Washington	G	unknown	33.33	0.92
MuVs/Washington.USA/9.17/FH16[G]	Buccal Swab	USA	Washington	G	up-to-date	23.17	0.93
MuVs/Washington.USA/8.17/FH17[G]	Buccal Swab	USA	Washington	G	up-to-date	28.83	0.92
MuVs/Washington.USA/9.17/FH18[G]	Buccal Swab	USA	Washington	G	up-to-date	31.84	0.84
MuVs/Washington.USA/8.17/FH19[G]	Buccal Swab	USA	Washington	G	unknown	32.16	0.93
MuVs/Washington.USA/15.17/FH20[G]	Buccal Swab	USA	Washington	G	up-to-date	22.25	0.93
MuVs/Washington.USA/2.17/FH21[G]	Buccal Swab	USA	Washington	G	up-to-date	26.50	0.92
MuVs/Washington.USA/2.17/FH22[G]	Buccal Swab	USA	Washington	G	not up-to-date	31.09	0.85
MuVs/Washington.USA/2.17/FH23[G]	Buccal Swab	USA	Washington	G	up-to-date	25.61	0.92
MuVs/Washington.USA/3.17/FH24[G]	Buccal Swab	USA	Washington	G	up-to-date	21.89	0.93
MuVs/Washington.USA/3.17/FH25[G]	Buccal Swab	USA	Washington	G	up-to-date	27.23	0.93
MuVs/Washington.USA/2.17/FH26[G]	Buccal	USA	Washington	G	up-to-date	29.08	0.93

	Swab						
MuVs/Washington.USA/5.17/FH27[G]	Buccal Swab	USA	Washington	G	up-to-date	24.53	0.93
MuVs/Washington.USA/52.16/FH28[G]	Buccal Swab	USA	Washington	G	unknown	34.28	0.74
MuVs/Washington.USA/1.17/FH29[G]	Buccal Swab	USA	Washington	G	up-to-date	33.14	0.64
MuVs/Washington.USA/5.17/FH30[G]	Buccal Swab	USA	Washington	G	unknown	33.27	0.63
MuVs/Washington.USA/9.17/FH31[G]	Buccal Swab	USA	Washington	G	up-to-date	34.94	0.66
MuVs/Washington.USA/30.17/FH32[G]	Buccal Swab	USA	Washington	G	not up-to-date	21.88	0.93
MuVs/Washington.USA/50.16/FH33[G]	Buccal Swab	USA	Washington	G	unknown	23.94	0.92
MuVs/Washington.USA/12.17/FH34[G]	Buccal Swab	USA	Washington	G	up-to-date	24.15	0.93
MuVs/Washington.USA/12.17/FH35[G]	Buccal Swab	USA	Washington	G	not up-to-date	28.12	0.93
MuVs/Washington.USA/16.17/FH36[G]	Buccal Swab	USA	Washington	G	up-to-date	25.15	0.93
MuVs/Washington.USA/17.17/FH37[G]	Buccal Swab	USA	Washington	G	unknown	25.71	0.93
MuVs/Washington.USA/17.17/FH38[G]	Buccal Swab	USA	Washington	G	unknown	26.45	0.93
MuVs/Washington.USA/17.17/FH39[G]	Buccal Swab	USA	Washington	G	up-to-date	26.69	0.93

MuVs/Washington.USA/17.17/FH40[G]	Buccal Swab	USA	Washington	G	up-to-date	21.78	0.93
MuVs/Washington.USA/51.16/FH41[G]	Buccal Swab	USA	Washington	G	unknown	23.56	0.93
MuVs/Washington.USA/9.17/FH42[G]	Buccal Swab	USA	Washington	G	up-to-date	23.29	0.93
MuVs/Washington.USA/10.17/FH43[G]	Buccal Swab	USA	Washington	G	up-to-date	24.50	1.00
MuVs/Washington.USA/19.17/FH44[G]	Buccal Swab	USA	Washington	G	unknown	27.26	0.93
MuVs/Washington.USA/49.16/FH45[G]	Buccal Swab	USA	Washington	G	unknown	30.24	0.93
MuVs/Washington.USA/51.16/FH46[G]	Buccal Swab	USA	Washington	G	unknown	25.69	0.93
MuVs/Washington.USA/2.17/FH47[G]	Buccal Swab	USA	Washington	G	up-to-date	24.04	0.93
MuVs/Washington.USA/4.17/FH48[G]	Buccal Swab	USA	Washington	G	up-to-date	20.15	0.93
MuVs/Washington.USA/4.17/FH49[G]	Buccal Swab	USA	Washington	G	up-to-date	31.31	0.93
MuVs/Washington.USA/5.17/FH50[G]	Buccal Swab	USA	Washington	G	unknown	31.14	0.85
MuVs/Washington.USA/6.17/FH51[G]	Buccal Swab	USA	Washington	G	unknown	26.59	0.92
MuVs/Washington.USA/10.17/FH52[G]	Buccal Swab	USA	Washington	G	not up-to-date	23.76	0.93
MuVs/Washington.USA/19.17/FH53[	Buccal	USA	Washington	G	unknown	22.25	0.93

G]	Swab						
MuVs/Washington.USA/2.17/FH54[G]	Buccal Swab	USA	Washington	G	up-to-date	24.47	0.84
MuVs/Washington.USA/49.16/FH55[G]	nasopharyngeal/throat swab	USA	Washington	G	unknown	28.39	0.84
MuVs/Washington.USA/11.17/FH56[G]	Buccal Swab	USA	Washington	G	unknown	25.31	1.00
MuVs/Washington.USA/12.17/FH57[G]	Buccal Swab	USA	Washington	G	unknown	32.79	0.93
MuVs/Washington.USA/2.17/FH58[G]	Buccal Swab	USA	Washington	G	up-to-date	23.20	0.93
MuVs/Washington.USA/3.17/FH59[G]	Buccal Swab	USA	Washington	G	up-to-date	26.24	0.93
MuVs/Washington.USA/4.17/FH60[G]	Buccal Swab	USA	Washington	G	not up-to-date	26.87	0.93
MuVs/Washington.USA/7.17/FH61[G]	Buccal Swab	USA	Washington	G	unknown	24.86	0.98
MuVs/Washington.USA/3.17/FH62[G]	Buccal Swab	USA	Washington	G	unknown	26.99	0.94
MuVs/Washington.USA/16.17/FH63[G]	Buccal Swab	USA	Washington	G	up-to-date	24.26	0.99
MuVs/Washington.USA/50.16/FH64[G]	Buccal Swab	USA	Washington	G	up-to-date	34.54	0.93
MuVs/Washington.USA/1.17/FH65[G]	Buccal Swab	USA	Washington	G	up-to-date	28.53	0.93
MuVs/Washington.USA/2.17/FH66[G]	Buccal	USA	Washington	G	unknown	23.51	0.93

	Swab						
MuVs/Washington.USA/3.17/FH67[G]	Buccal Swab	USA	Washington	G	up-to-date	29.70	0.93
MuVs/Washington.USA/4.17/FH68[G]	Buccal Swab	USA	Washington	G	up-to-date	27.07	0.93
MuVs/Washington.USA/21.17/FH69[G]	Buccal Swab	USA	Washington	G	not up-to-date	22.46	0.93
MuVs/Washington.USA/4.17/FH70[G]	Buccal Swab	USA	Washington	G	unknown	25.32	0.93
MuVs/Washington.USA/4.17/FH71[G]	Buccal Swab	USA	Washington	G	up-to-date	25.92	0.93
MuVs/Washington.USA/5.17/FH72[G]	Buccal Swab	USA	Washington	G	unknown	22.74	0.93
MuVs/Washington.USA/20.17/FH73[G]	Buccal Swab	USA	Washington	G	up-to-date	28.59	0.93
MuVs/Washington.USA/22.17/FH74[G]	Buccal Swab	USA	Washington	G	up-to-date	28.84	0.93
MuVs/Washington.USA/52.16/FH75[G]	Buccal Swab	USA	Washington	G	up-to-date	27.02	0.93
MuVs/Washington.USA/12.17/FH76[G]	Buccal Swab	USA	Washington	G	not up-to-date	25.15	0.93
MuVs/Washington.USA/1.17/FH77[G]	Buccal Swab	USA	Washington	G	up-to-date	34.73	0.92
MuVs/Washington.USA/12.17/FH78[G]	Buccal Swab	USA	Washington	G	unknown	27.05	0.90
MuVs/Washington.USA/16.17/FH79[G]	Buccal Swab	USA	Washington	G	up-to-date	27.44	0.93

MuVs/Washington.USA/19.17/FH80[G]	Buccal Swab	USA	Washington	G	unknown	29.00	0.93
MuVs/Washington.USA/20.17/FH81[G]	Buccal Swab	USA	Washington	G	not up-to-date	27.85	0.93
MuVs/Washington.USA/20.17/FH82[G]	Buccal Swab	USA	Washington	G	up-to-date	33.04	0.84
MuVs/Washington.USA/29.17/FH83[G]	Buccal Swab	USA	Washington	G	not up-to-date	32.28	0.93
MuVs/Washington.USA/2.17/FH84[G]	Buccal Swab	USA	Washington	G	not up-to-date	23.08	0.84
MuVs/Wisconsin.USA/16.14/FH85[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.76
MuVs/Wisconsin.USA/20.14/FH86[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.58
MuVs/Wisconsin.USA/15.06/FH87[H]	unknown	USA	Wisconsin	H	unknown	unknown	0.53
MuVs/Missouri.USA/32.16/FH88[G]	unknown	USA	Missouri	G	unknown	unknown	0.78
MuVs/Wisconsin.USA/15.17/FH89[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.78
MuVs/Alabama.USA/11.17/FH90[G]	unknown	USA	Alabama	G	unknown	unknown	0.80
MuVs/Wisconsin.USA/15.06/FH91[A]	unknown	USA	Wisconsin	A	unknown	unknown	0.71
MuVs/Alabama.USA/19.17/FH92[G]	unknown	USA	Alabama	G	unknown	unknown	0.77
MuVs/Wisconsin.USA/37.06/FH93[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.69
MuVs/Washington.USA/9.17/FH94[K]	Buccal Swab	USA	Washington	K	unknown	29.13	0.63
MuVs/Washington.USA/11.17/FH95[G]	Buccal Swab	USA	Washington	G	up-to-date	28.52	0.77
MuVs/Washington.USA/11.17/FH96[G]	Buccal Swab	USA	Washington	G	up-to-date	36.91	0.76

MuVs/Washington.USA/12.17/FH97[G]	Buccal Swab	USA	Washington	G	up-to-date	35.13	0.63
MuVs/Washington.USA/14.17/FH98[G]	Buccal Swab	USA	Washington	G	not up-to-date	29.59	0.76
MuVs/Wisconsin.USA/41.06/FH99[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.77
MuVs/Washington.USA/19.17/FH100[G]	Buccal Swab	USA	Washington	G	up-to-date	29.44	0.78
MuVs/Missouri.USA/28.17/FH101[G]	unknown	USA	Missouri	G	unknown	unknown	0.80
MuVs/Ohio.USA/2.18/FH102[G]	unknown	USA	Ohio	G	unknown	unknown	0.76
MuVs/Washington.USA/4.17/FH103[G]	Buccal Swab	USA	Washington	G	up-to-date	34.19	0.56
MuVs/Washington.USA/5.17/FH104[G]	Buccal Swab	USA	Washington	G	up-to-date	31.96	0.74
MuVs/Washington.USA/6.17/FH105[G]	Buccal Swab	USA	Washington	G	up-to-date	36.53	0.65
MuVs/Washington.USA/7.17/FH106[G]	Buccal Swab	USA	Washington	G	not up-to-date	27.98	0.67
MuVs/Wisconsin.USA/7.07/FH107[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.80
MuVs/Wisconsin.USA/11.07/FH108[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.94
MuVs/Wisconsin.USA/11.07/FH109[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.94
MuVs/Wisconsin.USA/16.14/FH110[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.92
MuVs/Wisconsin.USA/20.14/FH111[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.94

MuVs/Wisconsin.USA/24.14/FH112[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.87
MuVs/Wisconsin.USA/29.14/FH113[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.93
MuVs/Missouri.USA/29.15/FH114[G]	unknown	USA	Missouri	G	unknown	unknown	0.84
MuVs/Wisconsin.USA/42.15/FH115[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.87
MuVs/Wisconsin.USA/42.15/FH116[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.88
MuVs/Wisconsin.USA/46.15/FH117[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.84
MuVs/Wisconsin.USA/2.16/FH118[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.91
MuVs/Ohio.USA/19.16/FH119[G]	unknown	USA	Ohio	G	unknown	unknown	0.93
MuVs/Wisconsin.USA/24.16/FH120[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.89
MuVs/Wisconsin.USA/19.16/FH121[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.93
MuVs/Missouri.USA/41.16/FH122[G]	unknown	USA	Missouri	G	unknown	unknown	0.85
MuVs/Missouri.USA/46.16/FH123[G]	unknown	USA	Missouri	G	unknown	unknown	0.88
MuVs/Missouri.USA/46.16/FH124[G]	unknown	USA	Missouri	G	unknown	unknown	0.90
MuVs/Missouri.USA/50.16/FH125[G]	unknown	USA	Missouri	G	unknown	unknown	0.88
MuVs/Wisconsin.USA/50.16/FH126[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.88
MuVs/Missouri.USA/2.17/FH127[G]	unknown	USA	Missouri	G	unknown	unknown	0.83
MuVs/Ohio.USA/2.17/FH128[G]	unknown	USA	Ohio	G	unknown	unknown	0.90

MuVs/Missouri.USA/7.17/FH129[G]	unknown	USA	Missouri	G	unknown	unknown	0.84
MuVs/Ohio.USA/7.17/FH130[G]	unknown	USA	Ohio	G	unknown	unknown	0.89
MuVs/Wisconsin.USA/15.06/FH131[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.81
MuVs/Ohio.USA/11.17/FH132[G]	unknown	USA	Ohio	G	unknown	unknown	0.86
MuVs/Missouri.USA/11.17/FH133[G]	unknown	USA	Missouri	G	unknown	unknown	0.85
MuVs/Missouri.USA/15.17/FH134[G]	unknown	USA	Missouri	G	unknown	unknown	0.85
MuVs/Missouri.USA/15.17/FH135[G]	unknown	USA	Missouri	G	unknown	unknown	0.86
MuVs/NorthCarolina.USA/11.17/FH136[G]	unknown	USA	NorthCarolina	G	unknown	unknown	0.84
MuVs/Wisconsin.USA/15.17/FH137[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.85
MuVs/Missouri.USA/15.17/FH138[G]	unknown	USA	Missouri	G	unknown	unknown	0.82
MuVs/Alabama.USA/15.17/FH139[G]	unknown	USA	Alabama	G	unknown	unknown	0.83
MuVs/Missouri.USA/19.17/FH140[G]	unknown	USA	Missouri	G	unknown	unknown	0.84
MuVs/Wisconsin.USA/19.17/FH141[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.85
MuVs/Washington.USA/8.17/FH142[G]	Buccal Swab	USA	Washington	G	up-to-date	25.33	0.86
MuVs/Washington.USA/11.17/FH143[G]	Buccal Swab	USA	Washington	G	up-to-date	28.34	0.87
MuVs/Washington.USA/12.17/FH144[G]	Buccal Swab	USA	Washington	G	unknown	29.66	0.85
MuVs/Washington.USA/14.17/FH145[G]	Buccal Swab	USA	Washington	G	up-to-date	21.45	0.91

MuVs/Washington.USA/15.17/FH146[G]	Buccal Swab	USA	Washington	G	up-to-date	27.09	0.84
MuVs/Washington.USA/18.17/FH147[G]	Buccal Swab	USA	Washington	G	up-to-date	28.86	0.88
MuVs/Washington.USA/20.17/FH148[G]	Buccal Swab	USA	Washington	G	up-to-date	26.59	0.82
MuVs/Washington.USA/23.17/FH149[G]	Buccal Swab	USA	Washington	G	unknown	33.05	0.84
MuVs/Washington.USA/23.17/FH150[G]	Buccal Swab	USA	Washington	G	up-to-date	32.33	0.84
MuVs/Washington.USA/28.17/FH151[G]	Buccal Swab	USA	Washington	G	up-to-date	24.18	0.88
MuVs/Washington.USA/16.17/FH152[G]	Buccal Swab	USA	Washington	G	up-to-date	27.41	0.85
MuVs/Wisconsin.USA/41.06/FH153[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.84
MuVs/Wisconsin.USA/7.07/FH154[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.94
MuVs/Missouri.USA/33.17/FH155[G]	unknown	USA	Missouri	G	unknown	unknown	0.85
MuVs/Alabama.USA/50.17/FH156[G]	unknown	USA	Alabama	G	unknown	unknown	0.85
MuVs/Ohio.USA/46.17/FH157[G]	unknown	USA	Ohio	G	unknown	unknown	0.84
MuVs/Washington.USA/49.16/FH158[G]	Buccal Swab	USA	Washington	G	unknown	30.55	0.84
MuVs/Wisconsin.USA/28.06/FH159[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.84
MuVs/Washington.USA/1.17/FH160[G]	Buccal Swab	USA	Washington	G	unknown	24.17	0.87

MuVs/Washington.USA/5.17/FH161[G]	Buccal Swab	USA	Washington	G	up-to-date	23.05	0.92
MuVs/Washington.USA/5.17/FH162[G]	Buccal Swab	USA	Washington	G	up-to-date	27.08	0.90
MuVs/Wisconsin.USA/51.15/FH163[G]	unknown	USA	Wisconsin	G	unknown	unknown	0.86
MuVs/Alabama.USA/7.17/FH164[G]	unknown	USA	Alabama	G	unknown	unknown	0.80
MuVs/Missouri.USA/24.17/FH165[G]	unknown	USA	Missouri	G	unknown	unknown	0.86
MuVs/Washington.USA/7.17/FH166[G]	Buccal Swab	USA	Washington	G	up-to-date	27.96	0.85

All genomes generated for this analysis are described above. Dates are formatted as Year-month-day. Vaccination status, Ct, and sample collection type are all available for the Washington samples. Genome coverage represents the total proportion of bases in the genome with at least 20x coverage for which we were able to call a base. Sites with <20x coverage were labelled as Ns. Only samples with at least 50% non-N bases were included in the analysis.

Supplemental Table 2: Mumps cases by age group

Age group	Mumps case count	2016-2017 average population in Washington[1]	Rate of cases per 100,000 individuals	Percentage of total cases
0 - 4	34	450,847	7.5	3.8%
5 - 9	104	462,951	22.5	11.7%
10 - 14	198	451,485	43.9	22.3%
15 - 19	214	455,612	47.0	24.1%
20 - 39	256	1,980,004	12.9	28.8%

40 - 64	80	2,348,529.5	3.4	10.0%
65+	2	1,097,571	0.2	0.22%
Unknown	1	NA	NA	0.11%

Supplemental Table 3: Outbreak characteristic and dataset composition

	counts in outbreak (%)	Count in dataset (%)
Up-to-date vaccination	574 (65%)	64 (58%)
Not up-to-date vaccination	86 (9.7%)	13 (12%)
Unknown vaccination status	229 (26%)	33 (30%)
Marshallese	465 (52%)	57 (52%)
Not Marshallese	424 (48%)	53 (48%)
Total	**889**	**110**

Supplemental References

1. Estimates of April 1 population by age, sex, race and Hispanic origin. https://www.ofm.wa.gov/washington-data-research/population-demographics/population-estimates/estimates-april-1-population-age-sex-race-and-hispanic-origin.s